AMPK, Mitochondrial Function, and Cardiovascular Disease

Shengnan Wu * and Ming-Hui Zou

Center for Molecular and Translational Medicine, Georgia State University, Atlanta, GA 30303, USA; mzhou@gsu.edu
* Correspondence: swu12@gsu.edu
Received: 11 June 2020; Accepted: 6 July 2020; Published: 15 July 2020

Abstract: Adenosine monophosphate-activated protein kinase (AMPK) is in charge of numerous catabolic and anabolic signaling pathways to sustain appropriate intracellular adenosine triphosphate levels in response to energetic and/or cellular stress. In addition to its conventional roles as an intracellular energy switch or fuel gauge, emerging research has shown that AMPK is also a redox sensor and modulator, playing pivotal roles in maintaining cardiovascular processes and inhibiting disease progression. Pharmacological reagents, including statins, metformin, berberine, polyphenol, and resveratrol, all of which are widely used therapeutics for cardiovascular disorders, appear to deliver their protective/therapeutic effects partially via AMPK signaling modulation. The functions of AMPK during health and disease are far from clear. Accumulating studies have demonstrated crosstalk between AMPK and mitochondria, such as AMPK regulation of mitochondrial homeostasis and mitochondrial dysfunction causing abnormal AMPK activity. In this review, we begin with the description of AMPK structure and regulation, and then focus on the recent advances toward understanding how mitochondrial dysfunction controls AMPK and how AMPK, as a central mediator of the cellular response to energetic stress, maintains mitochondrial homeostasis. Finally, we systematically review how dysfunctional AMPK contributes to the initiation and progression of cardiovascular diseases via the impact on mitochondrial function.

Keywords: mitochondrial function; AMPK; cardiovascular disease

1. Introduction

Cells constantly coordinate their metabolism to satisfy their energy needs and respond to the use of nutrients. Eukaryotes have developed a highly adaptive complex, the serine/threonine kinase adenosine monophosphate (AMP)-activated protein kinase (AMPK), to sense low cellular adenosine triphosphate (ATP) levels [1]. Under conditions of insufficient energy, AMPK activates upon its binding with AMP or adenosine diphosphate (ADP) [1]. Once activated, AMPK redirects metabolism toward increased catabolism or decreased anabolism through the phosphorylation of key proteins across multiple pathways, including protein synthesis (e.g., mammalian target of rapamycin complex (1) [2,3], lipid homeostasis (e.g., acetyl coenzyme A carboxylase, ACC) [4,5], glucose metabolism (e.g., phosphofructokinase (2) [6], and mitochondrial homeostasis (e.g., peroxisome proliferator-activated receptor gamma coactivator (PGC) 1 alpha, PGC1α) [7]. Besides, AMPK can adjust intracellular metabolism in a prolonged way by aiming at transcriptional regulators (e.g., forkhead box Os) [8]. Overall, activated AMPK balances energy levels by raising ATP synthesis and/or reducing ATP consumption. Thanks to its core roles in intracellular metabolism, dysregulation of AMPK is prevalent in obesity, diabetes, cancer, and cardio-metabolic diseases. AMPK is a prospective pharmacological target [9–15], notably for treating type 2 diabetes [16–18].
2. AMPK Structure and Regulation

2.1. AMPK Structure

AMPK, a heterotrimeric complex, is composed of a catalytic α-subunit and beta (β) and gamma (γ) regulatory subunits [19]. In humans, each subunit has multiple distinct isoforms encoded by different genes: the α-subunit has two isoforms, α1 and α2, encoded by gene PRKAA1 and PRKAA2, respectively [20]; the β-subunit has two isoforms, β1 and β2, encoded by gene PRKAB1 and PRKAB2, respectively [21]; and the γ-subunit has three isoforms, γ1, γ2, and γ3, encoded by gene PRKAG1, PRKAG2, and PRKAG3, respectively [22]. Each AMPK complex is comprised of an α-subunit, a β-subunit, and a γ-subunit, and all possible combinations produce 12 different AMPK complexes [23].

The α-subunit contains the kinase domain and a critical residue (Thr174 in α1-subunit and Thr172 in α2-subunit, hereafter referred to as Thr172) that is phosphorylated by upstream kinases [1]. The α-subunit is essential, and a double knockout (KO) of AMPKa1 and AMPKa2 in mice gives rise to embryonic lethality [24]. The β-subunit includes a carbohydrate-binding module that grants AMPK to bind to glycogen [25]. The γ-subunit allows AMPK to react to changes in the level of AMP, ADP, and ATP, as it includes four tandem cystathionine β synthase motifs that allow AMPK to bind adenine nucleotides [26].

2.2. Regulation of AMPK

2.2.1. AMPK is Activated by AMP/ADP and Inhibited by ATP

AMPK is activated by energy stress and/or cellular stress in response to increased ATP consumption (e.g., exercise, cell proliferation, and anabolism) or decreased ATP production (e.g., low glucose levels, oxidative stress, and hypoxia), which are sensed as low ratios of ATP-to-AMP/ADP. Binding of AMP, and to a lesser degree ADP, to the γ-subunit stimulates AMPK activity via three mechanisms [27–29]. First, AMP has been hypothesized to promote the phosphorylation of Thr172 by directly stimulating the activity of the upstream kinase, or by an allosteric mechanism that would render AMPK a suitable substrate for the upstream kinase [30–32]. Liver kinase B 1 (LKB1) [32] and calcium/calmodulin-dependent protein kinase kinase (CAMKK) 2 [33,34] can be employed as the two main mammalian upstream molecules that phosphorylate AMPK. Second, AMP protects Thr172 against dephosphorylation by phosphatases [28,35–37]. Third, AMP causes the allosteric activation of AMPK that has already been phosphorylated on Thr172. Activation loop phosphorylation increases AMPK activity by about 100-fold, while allosteric regulation changes AMPK activity up to tenfold in mammalian cells and about twofold in recombinant, bacterially produced AMPK [26,28,38,39]. Lastly, allosteric AMPK activation can also occur in non-phosphorylated AMPK, with even higher fold activation than phosphorylated AMPK [40].

2.2.2. Regulation of AMPK by Reactive Oxygen Species (ROS)

ROS are plenty of free radicals and chemically reactive molecules derived from oxygen molecule [41]. Most ROS are generated as byproducts of mitochondrial electron transportation from the reduction of molecular oxygen to produce superoxide [41]. The sequential reduction of superoxide gives rise to the generation of various ROS that includes hydroxyl radical, hydrogen peroxide, and hydroxyl ion [41]. The actions of ROS can be both beneficial and detrimental [41]. The beneficial aspects of ROS at physiological levels are usually related to their effects in cell survival signaling cascades [41]. Excessive production of ROS, usually termed oxidative stress, are caused by increased production and/or insufficient presence of endogenous antioxidants [41]. Oxidative stress is considered detrimental because of its damage to fats, deoxyribonucleic acid, and proteins in a cell, which can lead to numerous diseases such as diabetes, cancer, neurodegenerative disease, and cardiovascular disease (CVD) [41]. Recent lines of evidence have demonstrated AMPK responsiveness to imbalanced redox status, thus bringing new insights into the networks of redox-stimulated signals upstream of AMPK (Table 1) [42–51]. For instance, Trolox, a vitamin E analog and antioxidant, reduces cellular ROS levels [51]. The addition of Trolox to mouse embryonic fibroblasts
(MEFs) resulted in basal AMPK activity reduction, as evidenced by the decreased phosphor-AMPKα at Thr172 [51].

Table 1. The type of reactive oxygen species (ROS) that activates adenosine monophosphate-activated protein kinase (AMPK). ATP, adenosine triphosphate; ADP, adenosine diphosphate; BAEC, bovine aortic endothelial cell; MEF, mouse embryonic fibroblast; VSMC, vascular smooth muscle cell; HUVEC, human umbilical vein endothelial cell; NOS, nitric oxide synthase; LKB1, liver kinase B 1; CAMKK2, calcium/calmodulin-dependent protein kinase kinase; PDK1, pyruvate dehydrogenase kinase 1; CRAC, calcium release-activated calcium.

| Stimuli                  | ROS                              | Cell Types       | Animal Strains | Mechanisms                              | Refs       |
|--------------------------|----------------------------------|------------------|----------------|-----------------------------------------|------------|
| N/A                      | Hydrogen peroxide                | H4IIEC3          | N/A            | PKCζ-LKB1                               | [42]       |
| N/A                      | Hydrogen peroxide                | HeLa             | N/A            | CaMKK                                   | [42]       |
| Berberine                | ROS, peroxynitrite Hydrogen peroxide | BAEC             | N/A            | LKB1                                    | [43]       |
| N/A                      | Hydrogen peroxide                | C2C12            | N/A            | ATP-to-ADP ratio                        | [44]       |
| N/A                      | Hydrogen peroxide                | NIH-3T3          | N/A            | AMP-to-ATP ratio                        | [45]       |
| N/A                      | Hydrogen peroxide NO, peroxynitrite | HEK293          | N/A            | ADP-to-ATP ratio                        | [46]       |
| N/A                      | Mitochondrial ROS                | MEF              | N/A            | N/A                                     | [51]       |
| Trolox                   | Physiological ROS                | MEF              | N/A            | N/A                                     | [51]       |
| Thromboxane receptor oxidase | Hydrogen peroxide              | VSMC             | N/A            | LKB1                                    | [52]       |
| Glucose oxidase          | Hydrogen peroxide                | HEK293, HeLa    | N/A            | AMP-to-ATP ratio                        | [53]       |
| Sodium nitroprusside     | Peroxynitrite NO                 | BAEC             | N/A            | N/A                                     | [54]       |
| Hypoxia-reoxygenation    | Peroxynitrite                   | BAEC             | N/A            | cSRC-PI3K-PDK1                          | [56]       |
| Hypoxia                  | Mitochondrial ROS                | AMPK α1−/2−/MEF  | N/A            | LKB1                                    | [57]       |
| Hypoxia                  | Cellular ROS                     | 143B, LKB1−/MEF  | N/A            | CRAC-CAMKK2                             | [58]       |
| 2-Deoxy-d-glucose        | Mitochondrial ROS                | BAEC             | N/A            | N/A                                     | [59]       |
| Metformin                | RNS                              | BAEC             | N/A            | cSRC-PI3K-LKB1 axis                     | [60]       |
Hydrogen Peroxide and AMPK Activation

AMPK is activated by hydrogen peroxide in various cell types. In H4IIEC3 cells, exogenous hydrogen peroxide transiently increased the level of phosphor-AMPK by LKB1 signaling, while exogenous hydrogen peroxide promoted AMPK phosphorylation in HeLa cells by CaMKK signaling [42]. Thromboxane A2 receptor (TPr) agonists increased the expression of nicotinamide adenine dinucleotide phosphate oxidase (NOX), thereby promoting the formation of superoxide in vascular smooth muscle cells (VSMCs) [52]. Exposure of cultured rat VSMCs to either TPr agonists or hydrogen peroxide led to AMPK activation in a time- and dose-dependent manner, as supported by the increased phosphor-AMPK at Thr172 and its downstream enzyme phosphor-ACC at Ser79 [61]. TPr agonists-activated AMPK was mediated by hydrogen peroxide, as demonstrated by the results showing overexpression of catalase (CAT) abolished Tpr agonists-induced AMPK activation [61]. In the meantime, LKB1 was activated by either TPr agonists or hydrogen peroxide [61]. Further, dominant negative mutation of LKB1 abolished both TPr agonists and hydrogen peroxide-stimulated AMPK activation, which suggested that hydrogen peroxide mediated TPr-triggered AMPK activation by LKB1 signaling [61]. These results collectively suggest that AMPK activation by hydrogen peroxide occurs through activation of either LKB1 or CaMKK, depending on the cell type.

ROS, in excess, can provoke energy stress and metabolic failure by direct oxidizing and inactivating enzymes of the tricarboxylic acid cycle, electron transport chain (ETC), and glycolysis [62,63]. It is well established that the ROS-induced energy stress strongly activates AMPK, which is likely the main mechanism of ROS-mediated AMPK activation. For instance, exposure of exogenous hydrogen peroxide to C2C12 cells led to a dose-dependent increase in AMPK activity by decreasing the ATP-to-ADP ratio [44]. Similarly, in NIH-3T3 cells, exogenous hydrogen peroxide transiently activated AMPK in a dose-dependent manner, which was associated with an increased AMP-to-ATP ratio [45]. Further, using HEK293 cells expressing AMPKγ2 R531G, an AMP-insensitive AMPK complex, AMPK cannot be activated by hydrogen peroxide [46]. These findings suggest that the target for hydrogen peroxide may not be AMPK itself, but components of the ETC, leading to a secondary effect on AMPK through changes to ADP, AMP, and ATP.

Alternatively, some studies showed that ROS directly activated AMPK independent of changes in ADP, AMP, and ATP. Exogenous or glucose oxidase-generated hydrogen peroxide induced direct S-glutathionylation on the AMPKα subunit at Cys299 and Cys304, which contributes to AMPK activation [48]. However, this view has been challenged with the fact showing that replacement of redox-sensitive cysteine residues with insensitive alanine residues does not affect hydrogen peroxide-induced AMPK activation [44,53].

Reactive Nitrogen Species (RNS) and AMPK Activation

Nitric oxide (NO) is produced by nitric oxide synthase (NOS) from l-arginine in the cell. RNS is produced beginning with the interaction between NO and superoxide to generate peroxynitrite. The sequential reaction of peroxynitrite with other molecules generates additional species of RNS, including dinitrogen oxide and nitrogen dioxide, as well as other types of chemically reactive molecules. ROS broadly include NO and its derivative RNS, both of which have been implicated in AMPK activation.

Compared with wild-type (WT) mice, neuronal NOS KO (nNOS−/−) mice showed both reduction of stroke damage and AMPK activation, which suggests a possible link between NO and AMPK activity in the context of stroke [47]. In the studies using cultured bovine aortic endothelial cells (BAECs), peroxynitrite significantly activated AMPK, as supported by increased phosphor-AMPK at Thr172 as well as increased phosphor-ACC, a downstream target of AMPK, at Ser79 [54]. In endothelial cells (ECs), studies showed that NO endogenously activated AMPK via elevating Ca2+ levels by the activation of soluble guanylyl cyclase [55]. Further, NO-triggered Ca2+ increase causes AMPK activation through CaMK2 signaling [55].

Exposure of ECs to chemically synthesized peroxynitrite acutely and significantly increased phosphorylation of AMPK and its downstream target ACC without affecting cellular AMP [56]. Hypoxia-reoxygenation (H/R) increased both AMPK and ACC phosphorylation in cultured BAECs,
which was prevented by either inhibition of NOS or overexpression of SOD, suggesting a role of peroxynitrite formed during H/R [56]. These results indicate that H/R via peroxynitrite activates AMPK in ECs [56]. It is debatable whether LKB1 participates in AMPK activation under hypoxia condition. Some studies showed that LKB1−/− MEFs under hypoxia for 30 min could not increase ACC phosphorylation [57], while LKB1−/− MEFs under hypoxia for 2 h activated AMPK through CaMKK2 [58], indicating that LKB1-induced AMPK activation occurs in a context-dependent manner.

NO- and RNS-dependent activation of AMPK is probably related to the ability of NO and RNS to suppress mitochondrial ATP production by modulating the ETC [64]. In fact, NO at nanomolar concentration can form a nitrosyl–heme complex to selectively and reversibly inhibit cytochrome c oxidase [65]. RNS at higher concentration can induce cysteine S-nitrosylation or tyrosine nitration in almost all the complexes of mitochondrial ETC [66,67].

2.2.3. AMPK is a Key Modulator for Maintaining Redox Homeostasis

AMPK is not only a sensor of redox signal, but also plays an anti-oxidative role once activated (Table 2). AMPK can diminish the superoxide production derived from either mitochondria or nicotinamide adenine dinucleotide phosphate oxidase (NOX). Further, AMPK also can suppress oxidative stress by upregulation of antioxidant gene expression.

Table 2. Activation of AMPK suppresses oxidative stress. AICAR, 5-aminomimidazole-4-carboxamide ribonucleotide; WT, wild-type; SD, Sprague Dawley; SOD, superoxide dismutase; CAT, catalase; UCP, uncoupling protein; NOX, nicotinamide adenine dinucleotide phosphate oxidase; PGC, peroxisome proliferator-activated receptor gamma coactivator.

| Stimuli | ROS | Cell Types | Animal Strains | Mechanisms | Refs |
|---------|-----|------------|----------------|------------|-----|
| A-769662 | Mitochondrial ROS | MEF | N/A | AMPK-PGC1α-CAT/SOD1/SOD2/UCP2 axis | [51] |
| Salicylate, AICAR | Mitochondrial ROS | RAEC, EA.hy926 bEnd.3 | WT SD rats | AMPK axis | [68] |
| Meglitol | Intracellular ROS | HUVEC | N/A | AMPKα2+/- mice | [69] |
| Metformin, AICAR | Mitochondrial ROS | HUVEC | N/A | AMPK-PGC1α-MnSOD axis | [70] |
| Metformin, AICAR | Superoxide | HUVEC | AMPKα2+/- mice | AMPK-UCP2 axis | [71] |
| Metformin | Oxidative stress | N/A | WT BALB/c mice | AMPK-PGC1/SOD1 axis | [72] |

AMPK Suppresses ROS

Mitochondrial ROS is increased by many atherosclerosis stimuli, including hyperglycemia, triglycerides, and oxidized low-density lipoprotein (oxLDL) [74–76]. One study reported that pharmacological activation of AMPK by either salicylate or 5-aminomimidazole-4-carboxamide ribonucleotide (AICAR) regulated mitochondrial morphology and ameliorated endothelial dysfunction through suppression of mitochondrial ROS-associated endoplasmic reticulum (ER) stress and the subsequent activation of the thioredoxin-interacting protein-associated NACHT, LRR and PYD domains-containing protein 3 inflammasome [68]. Miglitol protected against endothelial cell damage from oxidative stress via inhibition of apoptosis and mitochondrial superoxide production by activation of the AMPK-eNOS axis [69].

Under basal conditions, in addition to mitochondrial ETC, NOX is another source of ROS production in ECs [77]. Inflammation-triggered endothelium activation generally gives rise to a large scale of ROS production that is mainly attributed to membrane-bound and/or cytosolic enzymes such
as NOX [78]. Further, NOX-induced ROS production can enhance ROS production from other sources such as mitochondrial ETC and xanthine oxidase (XO) [77,79,80]. Analysis of AMPKa2 KO ECs and AMPK α2-silenced human umbilical vein endothelial cells (HUVECs) indicated that suppression of AMPK could increase NOX expression, NOX-mediated superoxide production, 26S proteasome activity, inhibitory subunit of nuclear factor kappa Bα degradation, and nuclear translocation of nuclear factor kappa B [70]. These studies indicated that AMPKa2 functions as a physiological suppressor of NOX and ROS production in ECs, in which way AMPK maintains the nonatherogenic and non-inflammatory phenotype of ECs [70].

AMPK Increases Antioxidant Potentials

The continuously produced ROS from mitochondrial ETC can be eliminated by antioxidant systems. It has been demonstrated that AMPK activation limited mitochondrial ROS generation in MEFs through PGC1α-dependent antioxidant response [51]. In this study, the potent AMPK activator A-769662 promoted an AMPK-dependent increase in several antioxidant genes, including CAT, superoxide dismutase (SOD)1, SOD2, and uncoupling protein 2 (UCP2). Moreover, a study using control or PGC1α-deficient MEFs with A-769662 showed that antioxidant gene expression was dependent on PGC1α expression. Similarly, in HUVECs, metformin normalized hyperglycemia-induced mitochondrial ROS production by inducing manganese SOD and promoting mitochondrial biogenesis through the activation of the AMPK–PGC1α pathway [71]. AMPK activation by either metformin or AICAR in HUVECs could suppress superoxide production by increasing the expression of the antioxidant gene UCP2 [72]. Further, AMPK activation by metformin lowered the grade of acute lung injury and acute respiratory distress syndrome via the inhibition of oxidative stress by upregulating SOD1 and PGC1α, thus providing potential value for treating such conditions in clinic [73].

3. Status of Mitochondrial Function Controls AMPK

3.1. Mitochondrial ATP and AMPK Activity

Mitochondria are considered the primary source of ATP production in the cell. As AMPK is a low ATP sensor that restores intracellular ATP homeostasis, almost every mitochondrial insult, including respiratory chain complexes inhibitors (e.g., metformin, berberine, rotenone, and oligomycin) [46,81–83], proton ionophores (e.g., carbonyl cyanide-4-phenylhydrazone and dinitrophenol) [46], and mitochondrial deoxyribonucleic acid depletion or mutation [84], can induce AMPK activation. To this extent, AMPK serves as a mitochondrial guardian in an ancient and conserved role that occurs in multiple species including mammalian cells, yeasts, worms, and flies.

3.2. Mitochondrial ROS and AMPK Activation

Mitochondrial ROS can activate AMPK under both resting and stress conditions (Table 1). One of the components of mitochondrial complex III, Rieske iron-sulfur protein, has the ability to modulate mitochondrial ROS production [85]. Silencing Rieske iron-sulfur protein resulted in mitochondrial ROS production at resting condition, along with the phosphorylation of both AMPK and its downstream effectors unc-51 like autophagy activating kinase 1 (ULK1) and ACC in MEFs [51]. The AMP-to-ATP ratio between control and Rieske iron-sulfur protein-knockdown cells is comparable [51]. There is a line of evidence revealing that AMPK activation by mitochondria-generated ROS is essential for 2-deoxy-d-glucose-induced autophagy in cultured ECs [59]. 2-deoxy-d-glucose activated AMPK in ECs, which was inhibited by either antioxidants such as Tempol and N-Acetyl-L-cysteine or overexpression of antioxidant enzymes such as SOD1 and CAT [59]. Further, 2-deoxy-d-glucose-induced autophagy in BAECs was blocked by CAT overexpression or AMPK knockdown [59]. The participation of AMPK in ROS-triggered autophagy was considered to be critical for endothelial cell survival under stress conditions [59]. The involvement of mitochondrial-derived ROS in AMPK activation has been challenged by a study using a mitochondrial redoxycler MitoParaquat, which triggers a selective and continuous production of mitochondrial superoxide at
complex I [86]. This study showed that mitochondria-generated ROS by MitoParaquat effectively change the thiol redox state of mitochondria in C2C12 cells without influencing AMPK activity, indicating that AMPK is unlikely be regulated by redox signaling in mitochondria [44].

Metformin has been reported to activate AMPK via mitochondrial-derived RNS production [60]. In cultured ECs, metformin activated AMPK, and likewise increased RNS production [60]. Further, either depletion of mitochondrial respiration or inhibition of NOS abolished the metformin-induced AMPK activation, implicating that metformin activates AMPK likely via the mitochondria-generated RNS [60]. Consistently, administration of metformin led to activation of AMPK in the heart and aorta of WT mice, but not in those of eNOS-deficient mice [60]. Further, metformin greatly increased the interaction between AMPK and LKB1 in mice, which suggested that LKB1 was involved in metformin-induced AMPK activation [60].

Berberine improves insulin sensitivity in type 2 diabetes models via the activation of AMPK by inhibiting mitochondrial complex I, a similar mechanism to metformin [83]. Previous work from our laboratory has demonstrated that complex I-associated ROS production is related to many protective effects using metformin [60]. In fact, it has been identified that mitochondrial-derived ROS participate in the underlying mechanism of berberine-induced AMPK activation [43]. However, whether ROS generation attributes to the defect of complex I by berberine remains to be further explored. In cultured BAECs, berberine dose- and time-dependently activated AMPK, which was evidenced by the increased AMPK phosphorylation at Thr172 and its downstream substrate ACC phosphorylation at Ser307 [43]. Concomitantly, berberine induced production of peroxynitrite. Pretreatment of NOS inhibitor and overexpression of SOD could blunt berberine-induced AMPK activation [43]. Further, pretreatment of mitochondria-targeted antioxidant tempol or overexpression of uncoupling proteins (UCPs) suppressed berberine-induced AMPK activation [43]. Consistently, depletion of mitochondrial ETC abolished the effects of berberine on AMPK activation in ECs [43]. Berberine greatly activated LKB1 by increasing its phosphorylation at Ser307, and silencing of LKB1 suppressed berberine-induced phosphorylation of AMPK at Thr172 in BAECs [43]. These results indicate that mitochondria-generated superoxide and peroxynitrite are essential for berberine-triggered AMPK activation in ECs [43].

4. AMPK Regulates Mitochondrial Homeostasis

Mitochondria are vital organelles with multiple roles in modulating energy supply, ROS generation, and intracellular calcium dynamics. Mitochondria continuously change in number, size, shape, and intracellular location to maintain homeostasis. Mitochondrial dysfunction occurs in the development of many CVDs such as atherosclerosis, ischemia-reperfusion (I/R) injury, hypertension, diabetes, cardiac hypertrophy, and heart failure (HF), owing to the production of ROS beyond control. Therefore, early control of mitochondrial dysfunction is a promising step in CVD prevention and therapy. A growing body of evidence has demonstrated the specific regulation of various aspects of mitochondrial homeostasis by AMPK. These aspects include control of mitochondrial number through stimulation of mitochondrial biogenesis, regulation of the shape of the mitochondrial network, mitochondrial quality control through mitophagy regulation, and mitochondrial calcium influx. Here, we summarize the recent advances in the research on the regulation of mitochondrial homeostasis by AMPK.

4.1. AMPK Promotes Mitochondrial Biogenesis

Mitochondrial biogenesis occurs in response to increased energy expenditure (e.g., exercise) to produce more ATP. AMPK promotes mitochondrial biogenesis in various tissues, including myocytes [87], adipocytes [88], macrophages [89], and hepatocytes [90]. Accumulating studies have established that AMPK is a central regulator of mitochondrial biogenesis, with most studies focused on its effect in skeletal muscle [91]. For instance, β-guanadinohipropionic acid-fed rats, in which skeletal muscle cells are in a state of chronic energy stress, showed chronic AMPK activation, increased nuclear respiratory factor 1 activity, and increased mitochondrial biogenesis in skeletal muscle [92]. Further, the AMPK-activating drug AICAR acted as an exercise mimic to promote mitochondrial biogenesis in muscle [93]. Mice expressing a dominant-negative AMPK mutant failed to induce mitochondrial biogenesis in
skeletal muscle under β-guanadinopropionic acid-induced energy stress [94]. The muscle-specific KO of AMPKa-subunit led to defects in mitochondrial biogenesis and function [87]. Mice lacking the AMPKβ1/β2 subunits showed a shortage of mitochondrial content in skeletal muscle [95]. Furthermore, overexpression of AMPKα3 (R225Q) mutant, which increased basal AMPK activity in mice, induced mitochondrial biogenesis in glycolytic skeletal muscle [96], while muscle-specific LKB1 KO mice failed to increase mitochondrial biogenesis after exercise [97].

Most genes involved in mitochondrial metabolism seem to be under the control of the PGCl family of coactivators, which is composed of PGClα, PGClβ, and PGCl-related coactivator [98]. Overexpression of PGClα in muscle is sufficient to convert type IIb (glycolytic) fibers into mitochondria-rich type II and type I fibers, which proves PGClα as a master regulator of mitochondrial biogenesis [99]. Interestingly, it has been reported that the transcriptional upregulation of several genes is involved in oxidative metabolism, including glucose transporter 4, mitochondrial genes, and PGClα itself, required PGClα upon AMPK activation [7]. Overexpression of a constitutively active AMPKα3 subunit increased PGClα expression [96]. Two sites on PGClα, Thr177 and Ser538, have been reported to be phosphorylated by AMPK both in vitro and in cells [7]. AMPK is also likely to regulate PGClα by several indirect mechanisms involving the AMPK-dependent modulation of p38 mitogen-activated protein kinases [100], histone deacetylase 5-myocyte enhancer factor 2 signaling [101,102], and sirtuin (SIRT)1 [103]. These findings collectively suggest that AMPK communicates with PGClα through a combination of mechanisms to regulate mitochondrial biogenesis.

4.2. AMPK Regulates Mitochondrial Dynamics

Notably, some stimuli that activate AMPK also can induce mitochondrial fission, underlining a potential link between AMPK and mitochondrial fission. In fact, both rotenone (inhibitor of complex I) and antimycin A (inhibitor of complex III) can induce mitochondrial fission, which was mediated by AMPK activation [82]. Moreover, direct pharmacological activation of AMPK using A-769662 or AICAR, without mitochondrial damage, is able to trigger mitochondrial fission, establishing a role of AMPK in regulating mitochondrial dynamics [82]. Proteomic and bioinformatic screens have identified mitochondrial fission factor (MFF), one of the primary receptors of dynamin-like protein (DRP1) in the mitochondrial outer membrane, as a novel substrate of AMPK [82,104]. In human bone osteosarcoma epithelial cells (U2OS) and MEFs, AMPK directly phosphorylated MFF on two sites, Ser155 and Ser173 [82,104]. A further study showed that AMPK-driven MFF phosphorylation at Ser155 and Ser172 is one potential mechanism to account for mitochondrial fission owing to mitochondrial respiration decline [82]. Indeed, AMPK activation caused an increased mitochondrial translocation of DRP1, an effect that disappeared in AMPK-insensitive MFF mutants [82]. Thus, AMPK regulates mitochondrial dynamics during energy stress by the MFF–DRP1 axis [82].

Another study reported that AMPK modulated mitochondrial fission via a mechanism of autophagy-dependent degradation of DRP1 [105]. In mouse aortic endothelium, ablation of either AMPKα1 or AMPKα2 gave rise to impaired autophagy, DRP1 stabilization, and aberrant mitochondrial fission [105]. Furthermore, autophagy blockage by either chloroquine or autophagy-related 7 gene knockdown increased DRP1 protein levels and triggered DRP1-mediated mitochondrial fission [105]. Autophagy activation by mammalian target of rapamycin (mTOR) inhibitor rapamycin or autophagy-related 7 overexpression induced DRP1 degradation and diminished mitochondrial fission in AMPKα2-null mice, which suggests that impaired autophagy accounts for DRP1 accumulation and mitochondrial fission [105]. In addition, degradation of DRP1 in the autophagy–lysosome pathway was mediated by the binding of DRP1 with autophagic receptor protein sequestosome 1/p62, leading to the translocation of DRP1 into the autophagosome [105]. Further studies suggest that DRP1-dependent mitochondrial fission is responsible for endothelial dysfunction in AMPK-deficient mice [105].

4.3. AMPK Regulates Mitophagy

AMPK has been shown to regulate autophagy both in yeast [106] and in mammalian cells [107]. AMPK regulates autophagy through ULK1 via two different mechanisms. First, AMPK directly
phosphorylates mTOR upstream regulator tuberous sclerosis complex 2 on Thr1227 and Ser1345 [3], and the subunit regulatory associated protein of mTOR complex 1 on Ser722 and Ser792 [2]. Both of these phosphorylation events contribute to reducing mTOR activity under energy stress conditions [2,3]. In turn, reduced mTOR activity removes the inhibitory phosphorylation on ULK1 to activate autophagy [108]. Second, AMPK directly phosphorylates ULK1 on four residues: Ser467, Ser555, Thr574, and Ser637 [109,110]. ULK1 phosphorylation by AMPK proved to be crucial for autophagy and cell survival during starvation and metabolic stress.

A series of later studies confirmed an essential role for ULK1 in mitophagy in various cells, such as brown adipocytes [111], myocytes [112], macrophages [113], and hepatocytes [114]. Strikingly, the AMPK–ULK1 axis is crucial not only for general autophagy, but also for mitophagy, as cells expressing ULK1 mutants resistant to AMPK phosphorylation accumulate defective mitochondria [110].

Inducers of mitophagy through the phosphatase and tensin homolog-induced putative kinase 1 (PINK1)– the E3 ubiquitin ligase (PARKIN) axis, such as the proton ionophore carbonylcyanide m-chlorophenylhydrazone [115], also strongly activate AMPK through the inhibition mitochondrial ATP synthesis [116]. Therefore, it is predictable that AMPK could be involved in the PINK1–PARKIN pathway. Indeed, a study using pressure overload-induced cardiac hypertrophy and HF models highlighted the role of AMPKα2 in the regulation of PINK1–PARKIN-dependent mitophagy [117]. It identified that, in the transverse aortic constriction (TAC) model, Ser495 in PINK1 underwent phosphorylation by AMPKα2 after dissipation of the mitochondrial inner membrane potential (∆Ψm) in cardiomyocytes [117]. This phosphorylation event was essential to efficiently recruit PARKIN to mitochondria and increase the rate of mitophagy during HF [117].

4.4. AMPK Regulates Mitochondrial Ca2+ Influx

An appropriate amount of mitochondrial matrix Ca2+ is required for the activation of a number of enzymes of the mitochondrial ETC and tricarboxylic acid cycle, thereby maintaining mitochondrial respiration and ATP production [118–120]. It is well established that rapid Ca2+ influx into mitochondrial matrix occurs through the mitochondrial Ca2+ uniporter (MCU), a specific channel located at the inner mitochondrial membrane. However, the regulatory mechanism of this uniporter is still not clear [121–123]. The capacity of cells to alter bioenergetics in response to the demands of various biological processes is essential for normal physiology. MCU shows optimal performance in skeletal muscle and cardiac muscle, which experience large or acute demands in their energy utilization [124–126]. Cell division is also a highly energy-demanding cellular process, but the coordination of energy sensing and production is poorly understood. To this end, some study demonstrated a novel role for MCU-mediated mitochondrial Ca2+ transients in maintaining energy homeostasis during mitosis [127]. During mitosis, AMPK phosphorylated and activated MCU, allowing Ca2+ entry into mitochondrial matrix to enhance mitochondrial respiration [127]. These findings establish a critical role for the AMPK–MCU axis in regulating mitochondrial Ca2+ signaling that connects energy sensing to proper mitotic progression [127].

5. AMPK, Mitochondrial Function, and CVDs

CVDs include a number of diseases that involve the heart or blood vessels. CVDs represent the leading cause of mortality worldwide. AMPK is widely expressed in the cardiovascular system. The α1 isoform predominates in VSMCs, ECs, adipocytes, and monocytes/macrophages, whereas cardiomyocytes express much higher amounts of the α2 isoform. Numerous studies have provided proof for the concept that AMPK is protective across diverse cell types in the cardiovascular system. Moreover, aberrant AMPK signaling is involved in the pathogenesis of various CVDs, including hypertension, atherosclerosis, and stroke. Recent studies suggest that there is therapeutic value in targeting the AMPK signaling. Here, we briefly summarize the AMPK mechanism of action in the context of CVDs, and then focus on recent discoveries concerning the regulation of mitochondrial homeostasis by AMPK in CVDs (Table 3). A thorough understanding of the AMPK-mitochondrial axis in CVDs is an attractive target for therapeutically intervening CVDs.
Table 3. AMPK, mitochondrial, cardiovascular diseases (CVDs), and complications. SIRT, sirtuin; APOE, apolipoprotein E; LDL, low-density lipoprotein; HFD, high-fat diet; PA, palmitate; TAC, transverse aortic constriction; DRP1, dynamin-like protein; PINK1, phosphatase and tensin homolog-induced putative kinase 1; FUNDC1, FUN14 domain containing 1; ETB, endothelin B; MAM, mitochondria-associated endoplasmic reticulum membrane.

| Reagents                      | Animal Strains                  | Disease Models | Culture Cells | Upstream of AMPK | Downstream of AMPK | Intracellular Effects | Cellular Effects | CVDs and Complications | Refs  |
|-------------------------------|---------------------------------|----------------|---------------|-------------------|--------------------|-----------------------|-------------------|------------------------|-------|
| Berberine                     | APOE<sup>+</sup> mice, APOE<sup>−/−</sup>/AMPKα2<sup>−/−</sup> mice | WD             | HUVEC         | Mitochondrial ROS | NRF1-UCP2 axis     | Oxidative stress      | Endothelial dysfunction | Atherosclerosis       | [128] |
| Fucoxanthin                   | N/A                             | oxLDL          | HUVEC         | N/A               | PKC-NOX-AKT-CREB-PGC1α axis | Oxidative stress; Mitochondrial dysfunction | Endothelial dysfunction | Atherosclerosis       | [129] |
| Salidroside                    | LDLR<sup>−/−</sup> mice         | HFD            | HUVEC         | AMP-to-ATP ratio  | PI3K/AKT-eNOS-NO axis | NO bioavailability    | Endothelial dysfunction | Atherosclerosis       | [130] |
| Mitochondria-targeted esculetin | APOE<sup>−/−</sup> mice        | AngII          | HAEC          | Mitochondrial ROS | eNOS-SIRT3-TFAM/PGC1α axis | Mitochondrial biogenesis | Endothelial dysfunction | Atherosclerosis       | [131] |
| N/A                           | AMPKα1<sup>−/−</sup> mice, AMPKα2<sup>−/−</sup> mice | N/A            | HUVEC, MAEC, PMEC | Mitochondrial ROS | UCP2               | Oxidative stress; NO bioavailability | Angiogenesis | Ischemia               | [132] |
| N/A                           |                                  | H9c2           | N/A           | Mitochondrial ROS | N/A                | DRP1-VDAC1/HK2/MPTP-PINK1/PARKIN axis | Mitophagy | Cardioprotection       | Ischemia | [133] |
| Melatonin                     | AMPKα<sup>−/−</sup> mice        | N/A            | CMEC          | N/A               | N/A                | Mitophagy             | Cell death | Ischemia/reperfusion  | [134] |
| Nitrite                       | WT mice                         | N/A            | H9c2          | PKA-DRP1-mitochondrial ROS axis | N/A                | Mitochondrial fission | Cell death | Ischemia/reperfusion  | [135] |
| The mitochondrial open reading frame of the 12S rRNA-c | WT mice                         | N/A            | N/A           | ETB and AT1       | N/A                | N/A                   | Vascular calcification | [136] |
| The translocator protein | WT mice | Balloon injury model, PDGF-BB | A10 | N/A | N/A | N/A | VSMC proliferation and migration | Neointima formation [137] |
|--------------------------|---------|-------------------------------|-----|-----|-----|-----|--------------------------------|--------------------------------|
| N/A                      | SIRT5<sup>−/−</sup> mice | TAC model | HEK293T | SIRT5-AMP/ATP axis | N/A | N/A | Cardiac dysfunction | Cardiac hypertrophy [138] |
| N/A                      | AMPKα2<sup>−/−</sup> mice | TAC model | HEK293T | N/A | PINK1/PARKIN axis | Mitophagy | Mitochondrial dysfunction | Cardiomyopathy | Cardiac hypertrophy [117] |
| N/A                      | AMPKα2<sup>−/−</sup> mice | STZ | H9c2, Cardiomyocyte | N/A | FUNDC1-MAMs axis | Mitochondrial fission | Mitochondrial dysfunction | Cardiomyopathy | Diabetes [139] |
| Melatonin                | N/A     | LPS | HUVEC | N/A | SERCA2a-Calcium-XO-ROS-DRP1 axis | Mitochondrial fission | Oxidative stress; Inflammation Mitochondrial biogenesis | Cell death | Obesity [141] |
| Corosolic acid           | WT mice | PA | RAEC, HUVEC | LKB1 | DRP1-NOX2-ROS-NLRP3 axis | Mitochondrial fission | Oxidative stress; Inflammation Mitochondrial biogenesis | Cardiac dysfunction | Obesity [142] |
| Punicalagin              | WT mice | HFD | Cardiomyocyte | ADP-to-ATP ratio | NRF2-Phase II enzyme | PGC1α | Oxidative stress | Heart disease | Obesit y [141] |
5.1. Atherosclerosis

Atherosclerosis, a disease in which the inside of an artery narrows as a result to plaque build-up, is a leading cause of mortality and morbidity in the Western world. The formation of atherosclerotic plaques initiates with an insult to the endothelium (endothelial dysfunction), resulting in the deposition of lipids in the tunica intima. Subsequent oxidation and uptake of lipids by macrophages and VSMCs generate foam cells and, eventually, the characteristic plaque [143].

Endothelial dysfunction is considered a critical early event for atherosclerosis, ahead of angiographic or ultrasonic evidence of atherosclerotic plaques [144]. Damage to the endothelium unbalances vasoconstriction and vasodilation and initiates a number of events that promote or exacerbate atherosclerosis, including increased permeability of endothelium, aggregation of platelet, adhesion of leukocyte, and generation of cytokine [143].

Oxidative stress caused by risk factors represents a major contributor to endothelial dysfunction as a common predisposing condition to atherosclerosis. AMPK has been shown to confer potent antioxidant defense, which thereby contributes to vascular health [145].

AMPK activation improves the function of endothelium by defending oxidative stress in atherosclerosis, as supported by AMPK-regulated UCP2 expression in ECs. UCP2 presents in the inner mitochondrial membrane and belongs to the family of mitochondrial anion carrier proteins. It appears that UCP2 has a main function of controlling ROS generation in diabetes, obesity, and atherosclerosis, although it was originally considered as a modulator of nonshivering thermogenesis. The absence of UCP2 in mice has been reported to increase oxidative stress [146,147] and amplify the progress of atherosclerotic plaques [148]. Furthermore, emerging evidence shows that UCP2 is a modulator of mitochondria-generated ROS [149,150]. Berberine, a Chinese traditional medicine, suppressed oxidative stress and reduced atherogenesis by a mechanism that contains AMPK-dependent UCP2 expression mediated by nuclear respiratory factor 1 [128].

Additional evidence supporting AMPK protection against oxidative stress is that AMPK negatively regulates NOX by reducing its phosphorylation and preventing p47phox’s translocation to membrane [70,151]. AMPK suppresses protein kinase C activity and prevents protein kinase C modulation of p47phox phosphorylation [152]. Fucoxanthin, a natural marine carotenoid extracted from edible seaweeds, alleviated oxidative damage of ECs treated by oxLDL. The protective effects of fucoxanthin were attributed to activation of the AMPK-protein kinase C-NOX signaling pathway. Moreover, the suppression of oxidative stress, in turn, blunted the activation of the protein kinase B-cyclic AMP-responsive element binding protein–PGC1α pathway, which ameliorated mitochondrial dysfunction and apoptosis [129].

NO bioavailability is indicative of the NO production and utilization in endothelium. Its decrease occurs in response to lipid infiltration, oxidative stress, and inflammatory factors, which play a vital role in endothelial dysfunction [153]. Decreased NO bioavailability, manifested as impaired vasodilation, represents one of the early signs of atherosclerosis [154]. Obesity, diabetes mellitus, smoking, chronic kidney disease, and so on participate in the pathogenesis of atherosclerosis via a mechanism of changing NO bioavailability [153]. It is expected to achieve therapeutic significance in atherosclerosis via the strategies intending to enhance endothelial function by improving NO bioavailability [155]. Increasing evidence suggests that AMPK is essential in maintaining NO bioavailability. In response to several stimuli, including metformin [156], adiponectin [157], thrombin [158], histamine [159], berberine [160], ciglitazone [161], and vascular endothelial growth factor [162], AMPK is activated and in turn acts as a direct activator of eNOS by phosphorylating its Ser1177 residue [163]. Further evidence also shows that AMPK lies upstream of the phosphatidylinositol-3-kinase-protein kinase B pathway, which also leads to eNOS activation and NO production [162,164,165].

Some studies reveal the correlation of AMPK–eNOS signaling with mitochondrial function in ECs in the context of atherosclerosis. Salidroside, a phenylpropanoid glycoside isolated from the medicinal plant Rhodiola rosea, efficiently decreased atherosclerotic plaque formation in LDL receptor-deficient mice [130]. The main mechanism relied on the stimulation of eNOS activation and
NO production through the AMPK-dependent activation of the phosphatidylinositol-3-kinase-protein kinase B pathway [130]. Jujuboside-induced AMPK activation was presumably related to the moderate depolarization of ΔΨm and subsequent increase of the cytosolic AMP-to-ATP ratio [130].

Given the causative role of mitochondrial ROS in endothelial dysfunction in vascular diseases, it would be beneficial to either suppress mitochondrial ROS or promote mitochondrial biogenesis to compensate ROS-induced mitochondrial loss. Esculetin has been reported to protect HUVECs against cytotoxicity after exposure of linoleic acid hydroperoxide, which is likely via its radical scavenging ability [166]. Mitochondria-targeted esculetin, capable of scavenging mitochondrial ROS, greatly alleviated angiotensin II-induced monocyte infiltration, atherosclerotic plaque formation, and serum pro-inflammatory cytokine production in apolipoprotein E KO mice [131]. In cultured human aortic endothelial cells, mechanism study showed that mitochondria-targeted esculetin significantly inhibited angiotensin II-induced cell death via enhancement of NO production via AMPK–eNOS signaling [131]. Notably, the anti-atherogenic effects of mitochondria-targeted esculetin are likely owing to the promotion of mitochondrial biogenesis through AMPK–SIRT3 signaling [131].

5.2. Ischemia

Ischemic vascular disease occurs when plaque builds up inside blood vessels and restricts normal blood flow. Angiogenesis is induced by ischemia and leads to new capillaries [167]. AMPK has been proven to be essential for ischemic angiogenesis; however, the mechanism by which AMPK promotes angiogenesis is poorly elucidated [165]. Study showed that inhibition of AMPK by either pharmacological inhibitor compound C or gene silencing significantly reduced tube formation in HUVECs [132]. Similarly, in comparison with the WT cells, tube formation in mouse arterial endothelial cells isolated from either AMPKα1−/− or AMPKα2−/− mice was significantly impaired, exhibiting oxidative stress and reduced expression of UCP2. Further, the impairment of tube formation in AMPKα1−/− or AMPKα2−/− cells could be normalized by adenoviral overexpression of UCP2 [132]. Alternatively, administration of NO donor, sodium nitroprusside, restored the tube formation in both AMPKα1−/− and AMPKα2−/− mice [132]. In comparison with WT mice, the ischemia-induced ser1177 phosphorylation of eNOS in thigh adductor muscles was blocked in both AMPKα1−/− and AMPKα2−/− mice [132]. Collectively, these results concluded that, in ECs, AMPK-dependent UCP2 expression together with eNOS phosphorylation promotes angiogenesis [132].

The heart is a highly aerobic organ [168]. Any condition of hypoxia may have a profound impact on cardiac function, and the majority of heart diseases are associated with cardiac hypoxia. According to the latest Global Burden of Disease Study, ischemic heart disease remained the leading global cause of death in 2017, accounting for 15.96% of total death worldwide [169]. Therefore, understanding molecular signaling transitions in cardiomyocytes under hypoxia may assist in the improvement of clinical treatments for heart disease.

In the heart, AMPK restores the ATP supply for cardiomyocytes and plays an essential role in both physiological states and stress conditions. Hypoxia activates AMPK through the ROS-mediated opening of calcium release-activated calcium channels [58,133]. A growing body of evidence has indicated that AMPK activation shows a protective effect on cardiomyocytes under myocardial ischemic injury [170]. Mechanically, AMPK increased glucose uptake and glucose transporter 4 translocation [171], decreased apoptosis, improved post-ischemic recovery, and limited myocardial infarction (MI) [172,173].

In cardiac muscle, chronic hypoxia induces oxygen-sensitive transcription to enhance carbohydrate metabolism, mitochondrial respiratory capacity, and the capability of mitochondrial energy supply. Thus, mitochondria were considered pivotal in cardiac regulation under hypoxia [174]. Under chronic hypoxia, PGC1α is upregulated, resulting in a subsequent increase of mitochondrial biogenesis [175]. However, with increasing mitochondria, the level of ROS is also increased as mitochondrial byproducts, which can result in oxidative damage of mitochondria [176]. Therefore, mitochondrial quality control is believed to be vital for maintaining the mitochondria in appropriate quality for cellular health. AMPK activation plays a crucial role in mitochondrial quality control under chronic hypoxia via modulating mitophagy in the heart [133]. Mitophagy increased
significantly in cardiomyocytes exposed to hypoxic conditions, which was accompanied by AMPK activation [133]. Notably, AMPK agonist AICAR dramatically increased mitophagy [133]. Consistently, when AMPK activation was blocked, mitophagy decreased as well, which subsequently gave rise to cardiomyocyte apoptosis [133]. These results suggest that AMPK participates in mitophagy regulation, which thereby provides a valuable therapeutic target for ischemic heart diseases.

5.3. I/R

I/R injury happens when blood is resupplied to tissue (reperfusion) after a period of shortage (ischemia). The absence of oxygen and nutrients from circulation during the ischemic period establishes a condition in which the restoration of blood results in oxidative damage rather than the recovery of normal function. Despite the successful revascularization of occluded vessels in the heart, reperfusion failure occurs in approximately 30% of patients with acute MI [177,178]. I/R injury is primarily induced by endothelial cell apoptosis in microcirculation. The apoptosis induces endothelial swelling, microvascular spasms, and capillary obstruction, which slows or even stops microcirculation blood flow following reperfusion [179]. I/R injury causes myocardial damage and increases 30-day mortality rates [180]. Vasculature I/R injury alleviates the efficiency of reperfusion therapy and compromises the clinical benefits of patients with acute MI [181]. Therefore, strategies to alleviate microvascular damage from I/R may increase crucial adjuvant modalities for patients. Carvedilol, a third-generation β blocker, is in clinical use for heart failure patients. Carvedilol modulates cardiac AMPK signaling to reduce ischemic insults by I/R [182]. Treatment of cardiomyocytes with carvedilol augmented phosphorylation of AMPK and its downstream substrate ACC, and ameliorated hypoxia-induced impairment [182]. Importantly, carvedilol treatment improved calcium homeostasis with rescuing the peak Ca²⁺ signal, the maximum rate of Ca²⁺ change during contraction and relaxation under hypoxia conditions [182].

Recent studies suggest that the cardioprotective effects of metformin on I/R are mediated by its activation of AMPK. Administration of metformin before ischemia or at reperfusion decreased myocardial injury in mice [183]. During early reperfusion, treatment with metformin augmented I/R-induced AMPK activation and significantly increased eNOS phosphorylation at ser1177 [183]. The beneficial actions of metformin disappeared in cardiac-specific dominant-negative AMPKa2 transgenic mice or eNOS deficient mice [183]. Further, metformin failed to increase eNOS Ser1177 phosphorylation at reperfusion in AMPKa2 deficient mice [183]. These findings provide important information that myocardial AMPK–eNOS activation by metformin following I/R led to cardioprotection [183].

Recently, mitochondrial homeostasis has been attributed as a critical regulator of cell death during cardiac I/R injury, especially mitochondrial fission and mitophagy [184]. Excessive mitochondrial fission aggravates cardiac I/R injury via alternating the balance of pro- and anti-survival factors [184]. Mitophagy is an intracellular process of selective removal of severely defective mitochondria from the entire pool to maintain appropriate mitochondrial quality and homeostasis [185]. However, an excessive mitophagy leads to consumption of most mitochondria, which results in energy shortage and eventual cellular death.

The cardiac microvascular system is primarily comprised by monolayer ECs, where blood supply and nutrient exchange occur in the heart. There are a few strategies to alleviate pathologies of microvascular I/R injury after percutaneous coronary intervention. Melatonin treatment reveals a protective role in cardiac microvasculature under I/R injury by activating AMPK [134]. Melatonin significantly decreased myocardial infarction, improved cardiac function, normalized blood flow, and lowered microcirculation perfusion impairment [134]. Histological analysis revealed that administration of melatonin restored the endothelial barrier, promoted eNOS expression, decreased inflammatory cell infiltration, and lowered endothelial damage in cardiac microcirculation endothelial cells [134]. Notably, all the beneficial effects of melatonin on microvasculature were abolished in AMPKa null mice [134]. In vitro mechanism studies showed that I/R triggered a DRP1-dependent mitochondrial fragmentation, which subsequently led to oligomerization of voltage-
dependent anion channel 1, liberation of hexokinase 2, opening of mitochondrial permeability transition pore, upregulation of PINK1–PARKIN signaling, and eventual mitophagy-mediated cell death [134]. Melatonin promoted cell survival via AMPKα activation, accompanied by phosphor-DRP1-S616 reduction and phosphor-DRP1-S637 elevation, which normalized mitochondrial fission [134]. The prevention of mitochondrial fission further restored the interaction between voltage-dependent anion channel 1 and hexokinase 2, stopped mitochondrial permeability transition pore opening, and PINK1–PARKIN activation, ultimately blunting cell death [134].

Nitrite is a dietary constituent that protects the heart against I/R injury in many animal models during both ischemia and preconditioning stage [186–192]. During ischemia, the protective effects of nitrite are attributed to the reduction of nitrite to NO by deoxygenated haem proteins. The action of nitrite in preconditioning stage is dependent on AMPK. In cultured rat H9c2 cardiomyoblasts treated with H/R, preconditioning with nitrite markedly attenuated cell death following hypoxia [135]. Further mechanism studies showed that nitrite activated protein kinase A, which in turn suppressed DRP1-dependent mitochondrial fission, augmented ΔΨm, and promoted superoxide production [135]. Moreover, ROS scavenging blocks AMPK activation and blunts nitrite-induced cardioprotection after H/R [135]. Notably, in vivo animal study showed consistent results that nitrite protected the heart against I/R injury through the activation of protein kinase A [135]. These data first demonstrated the connection between nitrite and mitochondrial morphology/function in normoxia, which is important for cardioprotection. The activation of AMPK signaling is required for the cardioprotective effect of nitrite in the preconditioning stage of I/R [135].

5.4. Vascular Calcification (VC)

VCs are mineral deposits on the walls of arteries and veins. VCs are common, but considered a potentially severe condition by increasing the risk of stroke and blood clots. Thus, it is necessary to study the pathogenesis of VCs and develop effective therapeutic strategies to treat VCs in the body.

The mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) is a bioactive mitochondrial-derived peptide shown to activate the AMPK pathway and modulate metabolic homeostasis [193]. Study showed that MOTS-c treatment significantly attenuated VCs induced by vitamin D3 and nicotine [136]. In parallel, phosphorylated AMPK increased and the expression of endothelin B (ETB) and angiotensin II receptor type 1 (AT1) receptors decreased after MOTS-c treatment [136]. ETB and AT1 are reportedly involved in AMPK pathway by binding to their receptors [194,195]. These findings indicate that MOTS-c may act as an inhibitor of VCs via suppressing the expression of AT1 and ETB receptors, probably by activating AMPK signaling [136].

5.5. Neointimal Hyperplasia Formation

Neointimal hyperplasia develops from excessive migration and proliferation of VSMCs from the medial layer toward the arterial lumen. Neointimal hyperplasia narrows the luminal diameter, leading to decreased blood flow and recurrence of anginal symptoms [196]. Thus, neointimal hyperplasia presents a significant clinical problem in patients with vascular disease.

The translocator protein (TSPO), an 18 kDa protein located at the outer mitochondrial membrane, is involved in the aberrant VSMC proliferation after angioplasty [137]. In a model of balloon-injured carotid arteries, TSPO expression was dramatically increased in carotid arteries [136]. Supplementation of PK11195, a ligand of TSPO, markedly reduced neointima formation in carotid arteries after balloon injury, through the suppression of the phenotype switching of VSMC [137]. Furthermore, it was found that PK11195 activated AMPK in A10 cells in a dose-dependent manner. An AMPK-specific inhibitor, compound C, abolished PK11195-induced inhibition of the proliferation and migration of platelet-derived growth factor-BB-treated A10 cells [137]. These results indicate that TSPO regulates neointimal formation after vascular injury via stimulating VSMC proliferation and migration, which is likely dependent on AMPK suppression [137]. TSPO could thus be a novel target for treating multiple CVDs, especially atherosclerosis and restenosis [137].
5.6. Cardiac Hypertrophy

Cardiac hypertrophy is the abnormal enlargement or thickening of the cardiac muscle, resulting from increases in cardiomyocyte size. The loss of AMPK activity is believed to be pro-hypertrophic because lines of molecular pathways that control cell growth are attenuated by AMPK activation [197–199]. In parallel, cardiac LKB1 null mice are associated with hypertrophy [200]. Furthermore, AMPK deficiency also contributes to cardiac hypertrophy induced by aging, neurohumoral activation, pressure overload, and MI [201]. Activation of AMPK by AICAR or metformin protects the heart from cardiac hypertrophy induced by aging and other stresses [202]. However, some pharmacological AMPK activators, such as MK-8722 [203], cause cardiac hypertrophy, which is considered the main side effect of pharmacological pan-AMPK activation [17].

SIRT5, a member of the nicotinamide adenine dinucleotide-dependent sirtuin family of protein deacetylases, removes posttranslational modifications including malonylation, glutarylation, and succinylation on lysine residues [204,205]. SIRT5, primarily localizing at the mitochondrial matrix, plays a vital role in mitochondrial function via increased mitochondrial nicotinamide adenine dinucleotide and ATP synthase activity [138]. SIRT5 deficiency attenuated ATP production from mitochondrial ETC, increased the AMP-to-ATP ratio, and in turn activated AMPK in both cultured cells and hearts under the conditions of energy stress [138]. Consistently, SIRT5 ablation attenuated cardiac hypertrophy and cardiac dysfunction in the TAC model, which is accompanied by the reduction of ATP, increase of AMP-to-ATP ratio, and enhancement of AMPK activity [138]. Thus, this study unveils a crucial role of SIRT5 in controlling cellular energy metabolism by AMPK activation upon energy stress, which further confirms the cardioprotective role of AMPK in left ventricular hypertrophy under the stress of pressure overload [138].

Accumulating evidence suggests that mitophagy impairment can induce cardiomyocyte death and HF [206–209]. The most studied mechanism for mitophagy in mammalian cells is mediated by the cytoplasmic E3 ubiquitin ligase PARKIN [210] and the mitochondrial membrane kinase PINK1 [211]. Recently, studies in pressure overload-induced cardiac hypertrophy and HF models highlight the role of AMPKα2 in the regulation of PINK1–PARKIN-dependent mitophagy [117]. In failing heart samples from patients or TAC mice, the isoform of AMPKα shifted from α2 to α1, which is associated with reduced mitophagy and dysfunctional mitochondria [117]. The adenovirus overexpression of AMPKα2 in hearts blocked TAC-induced chronic HF via promoting mitophagy and mitochondrial function [117]. In contrast, AMPKα2−/− mice showed an exacerbated progression of TAC-induced HF through defective cardiac mitophagy [117]. Further, ser995 in PINK1 underwent phosphorylation by AMPKα2 upon the dissipation of DΨ m in cardiomyocytes [117]. This phosphorylation proved critical for the efficient recruitment of PARKIN to mitochondria to initiate mitophagy during HF [117].

6. Cardio-Metabolic Diseases

6.1. Diabetes

Diabetes is a group of metabolic disorders featured by hyperglycemia over a prolonged time. The increased prevalence of diabetes was related to many factors, including diet, sedentary lifestyle, obesity, and aging [212,213]. CVD, accounting for over half of diabetic patients, is a major inducible factor of mortality in diabetic patients [214]. Endothelial dysfunction, the initial step of CVDs, is considered as a core modulator of vascular impairment in diabetes [215]. Endothelial dysfunction is attributed to many causes, including oxidative stress, chronic inflammation, and endothelium activation, in diabetes, which exhibits excessive free fatty acid (FFA), insulin resistance, and/or hyperglycemia [216,217].

In diabetes, mitochondrial dysfunction induces and aggravates macrovascular complications [218,219]. A line of evidence indicates that mitochondrial dynamics plays a pivotal role in endothelial dysfunction during macrovascular complications [220,221]. Both the conditions of hyperlipidemia and hyperglycemia impair mitochondrial dynamics by shifting the balance to excessive mitochondrial fission, leading to mitochondrial ROS over production and ETC impairment [221–223].
Additionally, mitochondria are a susceptible target of oxidative damage, which causes a malicious circle of events in ECs [224–226]. Thus, correcting the imbalance in mitochondrial dynamics during diabetes-induced endothelial dysfunction could improve patient outcomes. DRP1 is a cytoplasmic guanosine-5’-triphosphatase that triggers mitochondrial division by binding with mitochondrial receptors. Studies showed that AMPK deletion promoted mitochondrial fragmentation in ECs by inhibiting the autophagy-dependent degradation of DRP1 [105]. Numerous anti-diabetic agents may improve endothelial function by targeting AMPK to impact mitochondrial dynamics [227]. Clusterin, which exerts beneficial effects in ECs under diabetic conditions (both type 1 and type 2), inhibits mitochondrial fragmentation while activating AMPK [228]. Empagliflozin exerted its protective roles via inhibition of AMPK-dependent mitochondrial fission [229]. Empagliflozin recovered the AMP-to-ATP ratio that is necessary for triggering AMPK activation [229]. In the meantime, DRP1-S616 phosphorylation was decreased, while DRP1-S637 phosphorylation was increased, ultimately leading to mitochondrial fission [229]. Vildagliptin improved mitochondrial dysfunction in diabetic ECs, possibly by blunting DRP1-dependent mitochondrial fission by inducing AMPK activation [230]. Therefore, attenuation of mitochondrial fission by means of activating AMPK may represent a promising approach for macrovascular complications in diabetic patients.

Diabetic cardiomyopathy (DCM), a severe complication of diabetes mellitus, is a descriptive terminology showing the presence of myocardial dysfunction without apparent clinical valvular disease, coronary artery disease, and other conventional cardiovascular risk factors like dyslipidemia and hypertension [231]. Despite the significance of this complication, the underlying mechanisms of DCM are still poorly understood [232].

The mitochondria-associated ER membranes (MAMs) are referred to as the contact points by which the ER communicates with mitochondria [233]. MAMs play a vital role in lipid transport, Ca^{2+} signaling, cell survival, and energy metabolism [234], and have been implicated in diseases including Alzheimer’s disease [235], cancer [236], lysosomal storage disease [237], diabetes mellitus [238,239], obesity, and metabolic disorders [240]. Recently, the role of MAMs in the initiation and progression of DCM has drawn attention. Study showed that mitochondrial outer membrane protein FUN14 domain containing 1 (FUNDC1) is essential for maintaining the MAM structure and ensuring appropriate Ca^{2+} transfer from the sarcoplasmic reticulum (i.e., ER in myocytes) to mitochondria in healthy hearts [241]. Further, cardiac-specific KO of FUNDC1 gave rise to cardiac dysfunction via damaging MAM formation. High glucose-driven inactivation of AMPK increased FUNDC1, resulting in aberrant MAM formation, mitochondrial Ca^{2+} increase, mitochondrial dysfunction, and cardiac dysfunction [139]. In addition, AMPK activation reversed DCM by suppressing high glucose-induced MAM formation, mitochondrial Ca^{2+} increase, and mitochondrial dysfunction in cultured mouse neonatal cardiomyocytes 139]. These findings illustrating the results of AMPK activation, likely via downregulation of FUNDC1-related MAMs, represent a new therapeutic avenue for treating DCM [139].

6.2. Inflammation

Vascular inflammation, featured by the excessive production of pro-inflammatory cytokines (e.g., tumor necrosis factor α and interleukin 1β), can be caused by blood flow disturbance, toxins, hyperlipidemia, and hyperglycemia. Vascular inflammation stimulates the production of chemoattractants and molecules such as monocyte chemotactic proteins and vascular cell adhesion molecule 1 in endothelium [242–244]. Recently, deep mechanistic studies into the cardiovascular protection of AMPK using endothelial or myelomonocytic cell-specific AMPK KO mice have revealed the potent anti-inflammatory properties of AMPK in hypertension [145].

Metformin has been proven as an anti-inflammatory, especially for the inflammation in diabetes and following postsurgical endotoxin [245–247]. Additionally, AICAR, an AMPK activator, plays anti-inflammatory roles in vascular cells both in vitro and in vivo [248–250]. Atheroprotective flow patterns often give rise to anti-inflammatory conditions of the endothelium. In the clinic, the pleiotropic effects of statins on vessels are mediated by its anti-inflammatory effect and its ability to improve NO bioavailability. As discussed previously, a similar general outcome of metformin,
AICAR, atheroprotective flow, and statins on ECs can be found through AMPK activation [245,250,251]. Indeed, studies have uncovered that AMPK exerted its anti-inflammatory roles on the vasculature partially via the inhibition of adhesion molecules and chemoattractants [248,249,252,253] by regulating signal transducer and activator of transcription 3, of nuclear factor kappa B, and p300 pathways [254–256].

AMPK was involved in inflammation-induced mitochondrial dysfunction and endothelial dysfunction. For instance, melatonin protected HUVECs against lipopolysaccharide-mediated apoptosis [140]. Lipopolysaccharide triggered cytosolic calcium overload, and in turn upregulated XO, whose activity is calcium-dependent [140]. Upregulation of XO was accompanied by excessive ROS production, resulting in the Ser616 phosphorylation as well as the mitochondrial migration of DRP1 [140]. DRP1-dependent mitochondrial fission triggered mitochondrial apoptotic pathway, as shown by the caspase 9 cleavage, ΔΨm decline, cytochrome c leakage, as well as increased expression of proapoptotic proteins [140]. Importantly, melatonin activated AMPK, which was associated with the upregulation of sarcoplasmic/endoplasmic reticulum calcium ATPase 2a [140]. Further, melatonin-activated AMPK-sarcoplasmic/endoplasmic reticulum calcium ATPase 2a axis prevented calcium overload, XO-dependent ROS overproduction, DRP1-mediated mitochondrial fission, and apoptosis in lipopolysaccharide-treated cells [140]. Collectively, this study demonstrated that melatonin induced endothelial cell apoptosis through activation of the AMPK-sarcoplasmic/endoplasmic reticulum calcium ATPase 2a pathway under conditions of inflammation [140].

6.3. Obesity

Obesity, a leading cause of preventable death worldwide, is prevalent in both children and adults and serves as one of the most significant public health problems [257]. Obesity is a medical disorder in which the excessive accumulation of body fat contributes to adverse health effects. Obesity-related type 2 diabetes patients often have elevated plasma FFAs, because of either increased amounts of FFAs released from large amounts of adipose tissue or impaired FFA clearance [258]. Elevated levels of plasma FFAs upset insulin signaling and often cause systemic metabolic imbalance. Hyperinsulinemia is a direct risk factor for atherosclerosis and other CVDs. Elevated plasma FFAs also cause inflammation, further contributing to CVDs.

The EC lining inside vascular walls serves as an interface between the surrounding tissue and circulating blood. Elevated levels of plasma FFAs, owing to their high density, could directly impair endothelial NO production, which is dependent on endothelial phosphatidylinositol-3-kinase-eNOS signaling. Thus, under diabetic conditions, ECs often have reduced eNOS activity and diminished NO production [259]. FFAs also contribute to a higher production of ROS and inflammation in ECs [260]. Collectively, inflammation, NO bioavailability, insulin resistance, and oxLDL are the main participating factors in obesity-related endothelial dysfunction [261].

Corosolic acid (CRA) is a natural triterpenoid with antioxidative activity. Study showed that CRA alleviated endothelial inflammation in obesity by activating AMPK [141]. CRA suppressed DRP1 activation by inducing DRP1 phosphorylation at Ser637, thus inhibiting mitochondrial fission in ECs in response to palmitate (PA) treatment [141]. CRA activated AMPK in a LKB1-dependent manner, and AMPK silencing abrogated its inhibitory effect on DRP1 activation and mitochondrial fission [141]. Concurrently, CRA suppressed PA-induced NOX2 activation, which was revealed by the reduced migration of p47phox to cell membrane and inhibition of gp91phox expression [141]. DRP1 knockdown attenuated PA-induced NOX2 activation, and knockdown of DRP1 or NOX2 suppressed PA-induced NACHT, LRR, and PYD domains-containing protein 3 inflammatory effect and, in the meantime, strengthened the inhibitory effects of CRA [141]. These data collectively demonstrated that CRA prevented mitochondrial fission by regulating DRP1 phosphorylation at Ser637 in an AMPK-dependent manner, contributing to the blockage of NOX2-related oxidative stress and suppressing NACHT, LRR, and PYD domains-containing protein 3 inflammasome in the endothelium [141].
Obesity is closely associated with cardiac disorders, which is assumed to be a consequence of the adaption to an oversupply of high-fat substrates [262, 263]. Increased body weight switches the substrate of the heart from fatty acid to sugar, resulting in fat accumulation around the heart and eventually inducing cardiac impairment and increasing the risk of MI [264, 265]. Risk factors such as oxidative stress, ER stress, inflammation, and mitochondrial dysfunction owing to fat accumulation have been reported to be highly connected with obesity-induced cardiac metabolic disorders and impairment.

AMPK activity was observed to be suppressed by high-fat diet (HFD) in diverse tissues, including white heart, adipose tissue, and liver [266]. HFD-induced AMPK deficiency contributed to the enhanced cardiomyocyte death in myocardial ischemia [267]. The loss of AMPK activity exacerbated cardiac hypertrophy and dysfunctional contractility of HFD-fed mice [268]. Cleq/tumor necrosis factor-related protein 9 exhibited anti-myocardial lipotoxicity effects and attenuated cardiac hypertrophy, likely via activation of the LKB1–AMPK signaling [269]. A direct functional connection between AMPK signaling and β-adrenergic responsiveness exists in the heart, and AMPK might be a valuable target to recover the decreased β-adrenergic responsive in the heart of obesity [270]. Given that AMPK activation has beneficial metabolic consequences for obesity, AMPK has emerged as a promising therapeutic target for diabetic patients. Two classes of anti-diabetic drugs, metformin and thiazolidinediones, can function at least partially through the activation of AMPK in liver and muscle.

A recent study of subjects with type 2 diabetes offered clear evidence of mitochondrial dysfunction in permeabilized right atrial cardiac fibers [271], suggesting improvement to mitochondrial function as a potential therapeutic strategy for obesity and its associated pathologies. Punicalagin, the major active component in pomegranate extract, protects against HFD-induced cardiac disorders by activating AMPK pathway and promoting mitochondrial biogenesis [142]. In Sprague Dawley rats, administration of pomegranate extract, composed of 40% punicalagin, effectively blocked HFD-induced cardiac accumulation of fat (e.g., cholesterol and triglycerides) and myocardial damage [142]. Concomitantly, pomegranate extract activated AMPK, which may be responsible for the intervention of mitochondrial loss through promoting mitochondrial biogenesis and the attenuation of oxidative stress by means of upregulating phase II enzymes in HFD hearts [142]. Cell culture study demonstrated that punicalagin was the main component of pomegranate extract that specifically activated AMPK in cardiomyocytes via quickly reducing the intracellular ATP-to-ADP ratio [142]. These findings collectively elucidated that punicalagin, by activating AMPK, prevented HFD-related cardiac disorders via modulating mitochondria as well as phase II enzymes [142].

7. Perspectives

It is well-accepted that AMPK activation plays protective roles across diverse CVDs. AMPK has emerged as a guardian of mitochondria because almost all mitochondrial insults can activate AMPK. However, the interplay within the AMPK–mitochondrial axis during the initiation and progression of CVDs is poorly investigated. Limited evidence has focused on mitochondrial dynamics, mitochondrial biogenesis, and mitophagy, the three common functions of mitochondria that have been studied by cell biologists. Far beyond our current knowledge are the structural and functional changes to mitochondria that may be amplified under disease conditions. Therefore, it would be advantageous for investigators in the field of CVDs to focus on observing, defining, and clarifying novel characteristics and properties of mitochondria, thus contributing to both cell biology and advancing disease treatments.

Author Contributions: Writing—original draft preparation, S.W.; writing—review and editing, M.-H.Z. and S.W. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the AHA Career Development Award (19CDA34760110). And the article processing charge (APC) was funded by the AHA Career Development Award (19CDA34760110).

Acknowledgments: We thank all current and former colleagues of M.-H.Z’s lab whose works have been cited in this work. We thank National Institutes of health for his continuous support for the last twenty years. Zou is
the Eminent Scholar in Molecular and Translational Medicine of Georgia Research Alliance. Wu was supported by an American Heart Association postdoctoral fellowship award (16POST29960011).

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

ACC, acetyl coenzyme A carboxylase; ADP, adenosine diphosphate; AICAR, 5-aminooimidazole-4-carboxamide ribonucleotide; AMP, adenosine monophosphate; AMPK, adenosine monophosphate-activated protein kinase; APOE, apolipoprotein E; AT1, angiotensin II receptor type 1; ATP, adenosine triphosphate; BAEC, bovine aortic endothelial cell; CaMKK, calcium/calmodulin-dependent protein kinase; CAT, catalase; CRA, corosolic acid; CVD, cardiovascular disease; CRAC, calcium release-activated calcium; DCM, diabetic cardiomyopathy; DRP1, dynamin-like protein; EC, endothelial cell; ER, endoplasmic reticulum; ETB, endothelin B; ETC, electron transport chain; FFA, free fatty acid; FUNDC1, FUN14 domain containing 1; HF, heart failure; HFD, high-fat diet; HUVEC, human umbilical vein endothelial cell; I/R, ischemia-reperfusion; KO, knockout; LDL, low-density lipoprotein; LKB1, liver kinase B1; MAM, mitochondria-associated endoplasmic reticulum membrane; MEF, mouse embryonic fibroblast; MFF, mitochondrial fission factor; MI, myocardial infarction; MOTS-c, the mitochondrial open reading frame of the 12S rRNA-c; mTOR, mammalian target of rapamycin; NADPH, nicotinamide adenine dinucleotide phosphate; nNOS, neuronal nitric oxide synthase; NO, nitric oxide; NOS, nitric oxide synthase; NOX, nicotinamide adenine dinucleotide phosphate oxidase; OX, xanthine oxidase; oxLDL, oxidized low-density lipoprotein; PA, palmitate; PGC, peroxisome proliferator-activated receptor gamma coactivator; PINK1, phosphatase and tensin homolog-induced putative kinase 1; PDK1, pyruvate dehydrogenase kinase 1; RNS, reactive nitrogen species; ROS, reactive oxygen species; SIRT, sirtuin; SOD, superoxide dismutase; TAC, transverse aortic constriction; TPR, thromboxane A2 receptor; TSPO, the translocator protein; UCP, uncoupling protein; ULK1, unc-51 like autophagy activating kinase 1; VC, vascular calcification; VSMC, vascular smooth muscle cell; WT, wild-type; ΔΨm, mitochondrial inner membrane potential.

**References**

1. Hardie, D.G.; Ross, F.A.; Hawley, S.A. AMPK: A nutrient and energy sensor that maintains energy homeostasis. *Nat. Rev. Mol. Cell Biol.* **2012,** 13, 251–262.
2. Gwinn, D.M.; Shackelford, D.B.; Egan, D.F.; Mihaylova, M.M.; Mery, A.; Vasquez, D.S.; Turk, B.E.; Shaw, R.J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. *Mol. Cell* **2008,** 30, 214–226.
3. Inoki, K.; Zhu, T.; Guan, K.L. TSC2 mediates cellular energy response to control cell growth and survival. *Cell* **2003,** 115, 577–590.
4. Carling, D.; Zammit, V.A.; Hardie, D.G. A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. *FEBS Lett.* **1987,** 223, 217–222.
5. Munday, M.R.; Campbell, D.G.; Carling, D.; Hardie, D.G. Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. *Eur. J. Biochem.* **1988,** 175, 331–338.
6. Marsin, A.S.; Bertrand, L.; Rider, M.H.; Deprez, J.; Beauloye, C.; Vincent, M.F.; Van den Berghe, G.; Carling, D.; Hue, L. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. *Curr. Biol.* **2000,** 10, 1247–1255.
7. Jager, S.; Handschin, C.; St-Pierre, J.; Spiegelman, B.M. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. *Proc. Natl. Acad. Sci. USA* **2007,** 104, 12017–12022.
8. Greer, E.L.; Oskoui, P.R.; Banko, M.R.; Maniar, J.M.; Gygi, M.P.; Gygi, S.P.; Brunet, A. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. *J. Biol. Chem.* **2007,** 282, 30107–30119.
9. Yuan, H.X.; Xiong, Y.; Guan, K.L. Nutrient sensing, metabolism, and cell growth control. *Mol. Cell* **2013,** 49, 379–387.
10. Garcia, D.; Shaw, R.J. AMPK: Mechanisms of cellular energy sensing and restoration of metabolic balance. *Mol. Cell* **2017,** 66, 789–800.
11. Steinberg, G.R.; Kemp, B.E. AMPK in health and disease. *Physiol. Rev.* **2009,** 89, 1025–1078.
12. Hardie, D.G. AMPK: A target for drugs and natural products with effects on both diabetes and cancer. *Diabetes* 2013, 62, 2164–2172.

13. Hardie, D.G. Targeting an energy sensor to treat diabetes. *Science* 2017, 357, 455–456.

14. Hardie, D.G.; Ross, F.A.; Hawley, S.A. AMP-activated protein kinase: A target for drugs both ancient and modern. *Chem. Biol.* 2012, 19, 1222–1236.

15. Guigas, B.; Viollet, B. Targeting AMPK: From ancient drugs to new small-molecule activators. *Exp. Suppl.* 2016, 107, 327–350.

16. Cokorinos, E.C.; Delmore, J.; Reyes, A.R.; Albuquerque, B.; Kjobstad, R.; Jorgensen, N.O.; Tran, J.L.; Jakar, A.; Cialdea, K.; Esquejo, R.M. et al. Activation of skeletal muscle ampk promotes glucose disposal and glucose lowering in non-human primates and mice. *Cell Metab.* 2017, 25, 1147–1159.e10.

17. Myers, R.W.; Guan, H.P.; Ehrhart, J.; Petrov, A.; Prahalada, S.; Tozzo, E.; Yang, X.; Kurtz, M.M.; Trujillo, M.; Gonzalez Trotter, D. et al. Systemic pan-AMPK activator MK-8822 improves glucose homeostasis but induces cardiac hypertrophy. *Science* 2017, 357, 507–511.

18. Steneberg, P.; Lindahl, E.; Dahl, U.; Lidh, E.; Straseviciene, J.; Backlund, F.; Kjellkvist, E.; Berggren, E.; Lundberg, I.; Bergqvist, I. et al. PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. *JCI Insight* 2018, 3.

19. Yan, Y.; Zhou, X.E.; Xu, H.E.; Melcher, K. Structure and physiological regulation of AMPK. *Int. J. Mol. Sci.* 2018, 19.

20. Stapleton, D.; Mitchelhill, K.I.; Gao, G.; Widmer, J.; Michell, B.J.; Teh, T.; House, C.M.; Fernandez, C.S.; Cox, T.; Witters, L.A. et al. Mammalian AMP-activated protein kinase subfamily. *J. Biol. Chem.* 1996, 271, 611–614.

21. Thornton, C.; Snowden, M.A.; Carling, D. Identification of a novel AMP-activated protein kinase beta subunit isoform that is highly expressed in skeletal muscle. *J. Biol. Chem.* 1998, 273, 12443–12450.

22. Cheung, P.C.; Salt, I.P.; Davies, S.P.; Hardie, D.G.; Carling, D. Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. *Biochem. J.* 2000, 346 Pt 3, 659–669.

23. Ross, F.A.; MacKintosh, C.; Hardie, D.G. AMP-activated protein kinase: A cellular energy sensor that comes in 12 flavours. *FEBS J.* 2016, 283, 2987–3001.

24. Viollet, B.; Athea, Y.; Mounier, R.; Guigas, B.; Zarrinpashneh, E.; Horman, S.; Lantier, L.; Hebrard, S.; Devin-Leclerc, J.; Beauloye, C. et al. AMPK: Lessons from transgenic and knockout animals. *Front. Biosci. (Landmark Ed)* 2009, 14, 19–44.

25. Hudson, E.R.; Pan, D.A.; James, J.; Lucoq, J.M.; Hawley, S.A.; Green, K.A.; Baba, O.; Terashima, T.; Hardie, D.G. A novel domain in AMP-activated protein kinase causes glycogen storage bodies similar to those seen in hereditary cardiac arrhythmias. *Curr. Biol.* 2003, 13, 861–866.

26. Xiao, B.; Heath, R.; Saiu, P.; Leiper, F.C.; Leone, P.; Jing, C.; Walker, P.A.; Haire, L.; Eccleston, J.F.; Davis, C.T. et al. Structural basis for AMP binding to mammalian AMP-activated protein kinase. *Nature 2007*, 449, 496–500.

27. Hardie, D.G.; Carling, D.; Gamblin, S.J. AMP-activated protein kinase: Also regulated by ADP? *Trends Biochem. Sci.* 2011, 36, 470–477.

28. Gowans, G.J.; Hawley, S.A.; Ross, F.A.; Hardie, D.G. AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. *Cell Metab.* 2013, 18, 556–566.

29. Ross, F.A.; Jensen, T.E.; Hardie, D.G. Differential regulation by AMP and ADP of AMPK complexes containing different gamma subunit isoforms. *Biochem. J.* 2016, 473, 189–199.

30. Hawley, S.A.; Boudeau, J.; Reid, J.L.; Mustard, K.J.; Udd, L.; Makela, T.P.; Alessi, D.R.; Hardie, D.G. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. *J. Biol.* 2003, 2, 28.

31. Shaw, R.J.; Kosmata, M.; Bardeesy, N.; Hurley, R.L.; Witters, L.A.; DePinho, R.A.; Cantley, L.C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. *Proc. Natl. Acad. Sci. USA* 2004, 101, 3329–3335.

32. Woods, A.; Johnstone, S.R.; Dickerson, K.; Leiper, F.C.; Fryer, L.G.; Neumann, D.; Schlattner, U.; Wallmann, T.; Carlson, M.; Carling, D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. *Curr. Biol.* 2003, 13, 2004–2008.
33. Fujiwara, Y.; Kawaguchi, Y.; Fujimoto, T.; Kanayama, N.; Magari, M.; Tokumitsu, H. Differential AMP-activated Protein Kinase (AMPK) Recognition mechanism of Ca\(^{2+}\)/calmodulin-dependent protein kinase kinase isoforms. *J. Biol. Chem.* 2016, 291, 13802–13808.

34. Hawley, S.A.; Fan, D.A.; Mustard, K.J.; Ross, L.; Bain, J.; Edelman, A.M.; Frenguelli, B.G.; Hardie, D.G. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. *Cell Metab.* 2005, 2, 9–19.

35. Xiao, B.; Sanders, M.J.; Underwood, E.; Heath, R.; Mayer, F.V.; Carmena, D.; Jing, C.; Walker, P.A.; Eccleston, J.F.; Haire, L.F. et al. Structure of mammalian AMPK and its regulation by ADP. *Nature* 2011, 472, 230–233.

36. Garcia-Haro, L.; Garcia-Gimeno, M.A.; Neumann, D.; Beullens, M.; Bollen, M.; Sanz, P. The PP1-R6 protein phosphatase holoenzyme is involved in the glucose-induced dephosphorylation and inactivation of AMP-activated protein kinase, a key regulator of insulin secretion, in MIN6 beta cells. *FASEB J.* 2010, 24, 5080–5091.

37. Joseph, B.K.; Liu, H.Y.; Francisco, J.; Pandya, D.; Donigan, M.; Gallo-Ebert, C.; Giordano, C.; Bata, A.; Nickels, J.T., Jr. Inhibition of AMP kinase by the protein phosphatase 2a heterotrimer, PP2APpp2r2d. *J. Biol. Chem.* 2015, 290, 10588–10598.

38. Sanders, M.J.; Ali, Z.S.; Hegarty, B.D.; Heath, R.; Snowden, M.A.; Carling, D. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thiopenopyridone family. *J. Biol. Chem.* 2007, 282, 32539–32548.

39. Davies, S.P.; Helps, N.R.; Cohen, P.T.; Hardie, D.G. 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. *FEBS Lett.* 1995, 377, 421–425.

40. Willows, R.; Sanders, M.J.; Xiao, B.; Patel, B.R.; Martin, S.R.; Read, J.; Wilson, J.R.; Hubbard, J.; Gamblin, S.J.; Carling, D. Phosphorylation of AMPK by upstream kinases is required for activity in mammalian cells. *Biochem. J.* 2017, 474, 3059–3073.

41. Alfadda, A.A.; Sallam, R.M. Reactive oxygen species in health and disease. *J. Biomed. Biotechnol.* 2012, 2012, 936486.

42. Liangpunsakul, S.; Wou, S.E.; Zeng, Y.; Ross, R.A.; Jayaram, H.N.; Crabb, D.W. Effect of ethanol on hydrogen peroxide-induced AMPK phosphorylation. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2008, 295, G1173–G1181.

43. Han, Y.; Wang, Q.; Song, P.; Zhu, Y.; Zou, M.H. Redox regulation of the AMP-activated protein kinase. *PLoS ONE* 2010, 5, e15420.

44. Hinchy, E.C.; Grusczczyk, A.V.; Willows, R.; Navaratnam, N.; Hall, A.R.; Bates, G.; Bright, T.P.; Krieg, T.; Carling, D.; Murphy, M.P. Mitochondria-derived ROS activate AMP-activated protein kinase (AMPK) indirectly. *J. Biol. Chem.* 2018, 293, 17208–17217.

45. Choi, S.L.; Kim, S.J.; Lee, K.T.; Kim, J.; Mu, J.; Birnbaum, M.J.; Soo Kim, S.; Ha, J. The regulation of AMP-activated protein kinase by H(2)O(2). *Biochem. Biophys. Res. Commun.* 2001, 287, 92–97.

46. Hawley, S.A.; Ross, F.A.; Chevtzoff, C.; Green, K.A.; Evans, A.; Fogarty, S.; Towler, M.C.; Brown, L.J.; Ogumbayo, O.A.; Evans, A.M. et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. *Cell Metab.* 2010, 11, 554–565.

47. McCullough, L.D.; Zeng, Z.; Li, H.; Landree, L.E.; McFadden, J.; Ronnett, G.V. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke. *J. Biol. Chem.* 2005, 280, 20493–20502.

48. Zmijewski, J.W.; Banerjee, S.; Bae, H.; Friggeri, A.; Lazarowski, E.R.; Abraham, E. Exposure to hydrogen peroxide induces oxidation and activation of AMP-activated protein kinase. *J. Biol. Chem.* 2010, 285, 33154–33164.

49. Xie, Z.; Dong, Y.; Zhang, M.; Cui, M.Z.; Cohen, R.A.; Riek, U.; Neumann, D.; Schlattner, U.; Zou, M.H. Activation of protein kinase C zeta by peroxynitrite regulates LKB1-dependent AMP-activated protein kinase in cultured endothelial cells. *J. Biol. Chem.* 2006, 281, 6366–6375.

50. Wu, Y.; Song, P.; Zhang, W.; Liu, J.; Dai, X.; Liu, Z.; Lu, Q.; Ouyang, C.; Xie, Z.; Zhao, Z. et al. Activation of AMPKalpha2 in adipocytes is essential for nicotine-induced insulin resistance in vivo. *Nat. Med.* 2015, 21, 373–382.
51. Rabinovitch, R.C.; Samborska, B.; Faubert, B.; Ma, E.H.; Gravel, S.P.; Andrzejewski, S.; Raissi, T.C.; Pause, A.; St-Pierre, J.; Jones, R.G. AMPK maintains cellular metabolic homeostasis through regulation of mitochondrial reactive oxygen species. *Cell Rep.* **2017**, *21*, 1–9.

52. Koupparis, A.J.; Jeremy, J.Y.; Muzaffar, S.; Persad, R.; Shukla, N. Sildenafil inhibits the formation of superoxide and the expression of gp47 NAD(P)H oxidase induced by the thromboxane A2 mimetic, U46619, in corpus cavernosal smooth muscle cells. *BJU Int.* **2005**, *96*, 423–427.

53. Auciello, F.R.; Ross, F.A.; Ikematsu, N.; Hardie, D.G. Oxidative stress activates AMPK in cultured cells primarily by increasing cellular AMP and/or ADP. *FEBS Lett.* **2014**, *588*, 3361–3366.

54. Zou, M.H.; Hou, X.Y.; Shi, C.M.; Nagata, D.; Walsh, K.; Cohen, R.A. Modulation by peroxynitrite of Akt- and AMP-activated kinase-dependent Ser1179 phosphorylation of endothelial nitric oxide synthase. *J. Biol. Chem.* **2002**, *277*, 32552–32557.

55. Zhang, J.; Xie, Z.; Dong, Y.; Wang, S.; Liu, C.; Zou, M.H. Identification of nitric oxide as an endogenous activator of the AMP-activated protein kinase in vascular endothelial cells. *J. Biol. Chem.* **2008**, *283*, 27452–27461.

56. Zou, M.H.; Hou, X.Y.; Shi, C.M.; Kirkpatrick, S.; Liu, F.; Goldman, M.H.; Cohen, R.A. Withdrawal: Activation of 5′-AMP-activated kinase is mediated through c-Src and phosphoinositide 3-kinase activity during hypoxia-reoxygenation of bovine aortic endothelial cells: Role of peroxynitrite. *J. Biol. Chem.* **2019**, *294*, 18016.

57. Emerling, B.M.; Weinberg, F.; Snyder, C.; Burgess, Z.; Mutlu, G.M.; Viollet, B.; Budinger, G.R.; Chandel, N.S. Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio. *Free Radic. Biol. Med.* **2009**, *46*, 1386–1391.

58. Mungai, P.T.; Waypa, G.B.; Jairaman, A.; Prakriya, M.; Dokic, D.; Ball, M.K.; Schumacker, P.T. Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels. *Mol. Cell. Biol.* **2011**, *31*, 3531–3545.

59. Wang, Q.; Liang, B.; Shirwany, N.A.; Zou, M.H. 2-Deoxy-D-glucose treatment of endothelial cells induces autophagy by reactive oxygen species-mediated activation of the AMP-activated protein kinase. *PLoS ONE* **2011**, *6*, e17234.

60. Zou, M.H.; Kirkpatrick, S.S.; Davis, B.J.; Nelson, J.S.; Wiles, W.G.t.; Schlattner, U.; Neumann, D.; Brownlee, M.; Freeman, M.B.; Goldman, M.H. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. *J. Biol. Chem.* **2004**, *279*, 43940–43951.

61. Zhang, M.; Dong, Y.; Xu, J.; Xie, Z.; Wu, Y.; Song, P.; Guzman, M.; Wu, J.; Zou, M.H. Thromboxane receptor activates the AMP-activated protein kinase in vascular smooth muscle cells via hydrogen peroxide. *Circ. Res.* **2008**, *102*, 328–337.

62. Avery, S.V. Molecular targets of oxidative stress. *Biochem. J.* **2011**, *434*, 201–210.

63. Cecarini, V.; Gee, J.; Fioretti, E.; Amici, M.; Angeletti, M.; Eleuteri, A.M.; Keller, J.N. Protein oxidation and cellular homeostasis: Emphasis on metabolism. *Biochim. Biophys. Acta* **2007**, *1773*, 93–104.

64. Piantadosi, C.A. Regulation of mitochondrial processes by protein S-nitrosylation. *Biochim. Biophys. Acta* **2012**, *1820*, 712–721.

65. Sarti, P.; Forte, E.; Giuffre, A.; Mastronico, D.; Magnifico, M.C.; Arese, M. The chemical interplay between nitric oxide and mitochondrial cytochrome c oxidase: Reactions, effectors and pathophysiology. *Int. J. Cell Biol.* **2012**, *2012*, 571067.

66. Almeida, A.; Cidad, P.; Delgado-Esteban, M.; Fernandez, E.; Garcia-Nogales, P.; Bolanos, J.P. Inhibition of mitochondrial respiration by nitric oxide: Its role in glucose metabolism and neuroprotection. *J. Neurosci. Res.* **2005**, *79*, 166–171.

67. Moncada, S.; Bolanos, J.P. Nitric oxide, cell bioenergetics and neurodegeneration. *J. Neurochem.* **2006**, *97*, 1676–1689.

68. Li, J.; Wang, Y.; Wang, Y.; Wen, X.; Ma, X.N.; Chen, W.; Huang, F.; Kou, J.; Qi, L.W.; Liu, B. et al. Pharmacological activation of AMPK prevents Drp1-mediated mitochondrial fission and alleviates endoplasmic reticulum stress-associated endothelial dysfunction. *J. Mol. Cell. Cardiol.* **2015**, *86*, 62–74.

69. Aoki, C.; Suzuki, K.; Yanagi, K.; Sato, H.; Niitani, M.; Aso, Y. Miglitol, an anti-diabetic drug, inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. *J. Pharmacol. Sci.* **2012**, *120*, 121–128.
70. Wang, S.; Zhang, M.; Liang, B.; Xu, J.; Xie, Z.; Liu, C.; Viollet, B.; Yan, D.; Zou, M.H. AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: Role of 265 proteasomes. *Circ. Res.* **2010**, *106*, 1117–1128.

71. Kukidome, D.; Nishikawa, T.; Sonoda, K.; Imoto, K.; Fujisawa, K.; Yano, M.; Motoshima, H.; Taguchi, T.; Matsumura, T.; Araki, E. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. *Diabetes* **2006**, *55*, 120–127.

72. Xie, Z.; Zhang, J.; Wu, J.; Viollet, B.; Zou, M.H. Upregulation of mitochondrial uncoupling protein-2 by the AMP-activated protein kinase in endothelial cells attenuates oxidative stress in diabetes. *Diabetes* **2008**, *57*, 3222–3230.

73. Wang, G.; Song, Y.; Feng, W.; Liu, L.; Zhu, Y.; Xie, X.; Pan, Y.; Ke, R.; Li, S.; Li, F. et al. Activation of AMPK attenuates LPS-induced acute lung injury by upregulation of PGC1alpha and SOD1. *Exp. Ther. Med.* **2016**, *12*, 1551–1555.

74. Cho, Y.E.; Basu, A.; Dai, A.; Heldak, M.; Makino, A. Coronary endothelial dysfunction and mitochondrial reactive oxygen species in type 2 diabetic mice. *Am. J. Physiol. Cell Physiol.* **2013**, *305*, C1033–1040.

75. Matsumoto, S.; Gotob, N.; Hishinuma, S.; Abe, Y.; Shimizu, Y.; Katano, Y.; Ishihata, A. The role of hypertriglyceridemia in the development of atherosclerosis and endothelial dysfunction. *Nutrients* **2014**, *6*, 1236–1250.

76. Zmiiewski, J.W.; Moelering, D.R.; Le Goffe, C.; Landar, A.; Ramachandran, A.; Darley-Usmar, V.M. Oxidized LDL induces mitochondrial associated reactive oxygen/nitrogen species formation in endothelial cells. *Am. J. Physiol. Heart Circ. Physiol.* **2005**, *289*, H852–H861.

77. Shen, H.M.; Liu, Z.G. JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. *Free Radic. Biol. Med.* **2006**, *40*, 928–939.

78. Ray, R.; Shah, A.M. NADPH oxidase and endothelial cell function. *Clin. Sci. (Lond)* **2005**, *109*, 217–226.

79. Cai, H. NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. *Circ. Res.* **2005**, *96*, 818–822.

80. Zinkevich, N.S.; Gutterman, D.D. ROS-induced ROS release in vascular biology: Redox-redox signaling. *Am. J. Physiol. Heart Circ. Physiol.* **2011**, *301*, H647–H653.

81. Rena, G.; Hardie, D.G.; Pearson, E.R. The mechanisms of action of metformin. *Diabetologia* **2017**, *60*, 1577–1585.

82. Toyama, E.Q.; Herzig, S.; Couchet, J.; Lewis, T.L., Jr.; Loson, O.C.; Hellberg, K.; Young, N.P.; Chen, H.; Polleux, F.; Chan, D.C. et al. Metabolism. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. *Science* **2016**, *351*, 275–281.

83. Turner, N.; Li, J.Y.; Gosby, A.; To, S.W.; Cheng, Z.; Miyoshi, H.; Taketo, M.M.; Cooney, G.J.; Kraegen, E.W.; James, D.E. et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: A mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. *Diabetes* **2008**, *57*, 1414–1418.

84. Wu, S.B.; Wu, Y.T.; Wu, T.P.; Wei, Y.H. Role of AMPK-mediated adaptive responses in human cells with mitochondrial dysfunction to oxidative stress. *Biochim. Biophys. Acta* **2014**, *1840*, 1331–1344.

85. Tormos, K.V.; Anso, E.; Hamanaka, R.B.; Eisenbart, J.; Joseph, J.; Kalyanaraman, B.; Chandel, N.S. Mitochondrial complex III ROS regulate adipocyte differentiation. *Cell Metab.* **2011**, *14*, 537–544.

86. Robb, E.L.; Gawel, J.M.; Aksentijevic, D.; Cocheme, H.M.; Stewart, T.S.; Shchepinova, M.M.; Qiang, H.; Prime, T.A.; Bright, T.P.; James, A.M. et al. Selective superoxide generation within mitochondria by the targetted redox cytosol MitoPparaquat. *Free Radic. Biol. Med.* **2015**, *89*, 883–894.

87. Lantier, L.; Fentz, J.; Mounier, R.; Leclerc, J.; Treebak, J.T.; Pehmoller, C.; Sanz, N.; Sakakibara, I.; Saint-Amand, E.; Rimbaud, S. et al. AMPK controls exercise endurance, mitochondrial oxidative capacity, and skeletal muscle integrity. *FASEB J.* **2014**, *28*, 3211–3224.

88. Gan, L.; Yan, J.; Liu, Z.; Feng, M.; Sun, C. Adiponectin prevents reduction of lipid-induced mitochondrial biogenesis via AMPK/ACC2 pathway in chicken adipocyte. *J. Cell. Biochem.* **2015**, *116*, 1090–1100.

89. Galic, S.; Fullerton, M.D.; Schertzler, J.D.; Sikkm, S.; Marcinko, K.; Walkley, C.R.; Izon, D.; Honeyman, J.; Chen, Z.P.; van Denderen, B.J. et al. Hematopoietic AMPK beta1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. *J. Clin. Invest.* **2011**, *121*, 4903–4915.

90. Inata, Y.; Kikuchi, S.; Samraj, R.S.; Hake, P.W.; O’Connor, M.; Ledford, J.R.; O’Connor, J.; Lahni, P.; Wolfe, V.; Piraino, G. et al. Autophagy and mitochondrial biogenesis impairment contribute to age-dependent
liver injury in experimental sepsis: Dysregulation of AMP-activated protein kinase pathway. *FASEB J*. 2018; 32, 728–741.

91. Reznick, R.M.; Shulman, G.I. The role of AMP-activated protein kinase in mitochondrial biogenesis. *J. Physiol.* 2006; 574, 33–39.

92. Bergeron, R.; Ren, J.M.; Cadman, K.S.; Moore, I.K.; Perret, P.; Pyypaert, M.; Young, L.H.; Semenkovich, C.F.; Shulman, G.I. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. *Am. J. Physiol. Endocrinol. Metab.* 2001; 281, E1340–E1346.

93. Narkar, V.A.; Downes, M.; Yu, R.T.; Embler, E.; Wang, Y.X.; Banayo, E.; Mihaylova, M.M.; Nelson, M.C.; Zou, Y.; Juguilon, H. et al. AMPK and PPARalpha agonists are exercise mimetics. *Cell* 2008; 134, 405–415.

94. Zong, H.; Ren, J.M.; Young, L.H.; Pyypaert, M.; Mu; J.; Binbaum, M.J.; Shulman, G.I. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. *Proc. Natl. Acad. Sci. USA* 2002; 99, 15983–15987.

95. O'Neill, H.M.; Maarbjerg, S.J.; Crane, J.D.; Jeppesen, J.; Jorgensen, S.B.; Schertzer, J.D.; Shyroka, O.; Kiens, B.; van Denderen, B.J.; Tarnopolsky, M.A. et al. AMP-activated protein kinase (AMPK) beta1beta2 muscle null mice reveal an essential role for AMPK in maintaining mitochondrial content and glucose uptake during exercise. *Proc. Natl. Acad. Sci. USA* 2011; 108, 16092–16097.

96. Garcia-Roves, P.M.; Osler, M.E.; Holmstrom, M.H.; Zierath, J.R. Gain-of-function R225Q mutation in AMP-activated protein kinase gamma3 subunit increases mitochondrial biogenesis in glycolytic skeletal muscle. *J. Biol. Chem.* 2008; 283, 35724–35734.

97. Tanner, C.B.; Madsen, S.R.; Hallowell, D.M.; Goring, D.M.; Moore, T.M.; Hardman, S.E.; Heninger, M.R.; Atwood, D.R.; Thomson, D.M. Mitochondrial and performance adaptations to exercise training in mice lacking skeletal muscle LKB1. *Am. J. Physiol. Endocrinol. Metab.* 2013; 305, E1018–E1029.

98. Scarpulla, R.C. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. *Biochim. Biophys. Acta* 2011; 1813, 1269–1278.

99. Lin, J.; Wu, H.; Tarr, P.T.; Zhang, C.Y.; Wu, Z.; Boss, O.; Michael, L.F.; Puigserver, P.; Isotani, E.; Olson, E.N. et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. *Nature* 2002; 418, 797–801.

100. Chaube, B.; Malvi, P.; Singh, S.V.; Mohammad, N.; Viollet, B.; Bhat, M.K. AMPK maintains energy homeostasis and survival in cancer cells via regulating p38/PGC-1alpha-mediated mitochondrial biogenesis. *Cell Death Discov.* 2015; 1, 15063.

101. Czubryt, M.P.; McNally, J.; Fishman, G.I.; Olson, E.N. Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) and mitochondrial function by MEF2 and HDAC5. *Proc. Natl. Acad. Sci. USA* 2003; 100, 1711–1716.

102. McGee, S.L. Exercise and MEF2-HDAC interactions. *Appl. Physiol. Nutr. Metab.* 2007; 32, 852–856.

103. Canto, C.; Gerhart-Hines, Z.; Feige, J.N.; Lagouge, M.; Noriega, L.; Milne, J.C.; Elliott, P.J.; Puigserver, P.; Auwerx, J. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. *Nature* 2009; 458, 1056–1060.

104. Ducommun, S.; Deak, M.; Sumpton, D.; Ford, R.J.; Nunez Galindo, A.; Kussmann, M.; Viollet, B.; Steinberg, G.R.; Foretz, M.; Dayon, L. et al. Motif affinity and mass spectrometry proteomic approach for the discovery of cellular AMPK targets: Identification of mitochondrial fission factor as a new AMPK substrate. *Cell. Signal.* 2015; 27, 978–988.

105. Wang, Q.; Wu, S.; Zhu, H.; Ding, Y.; Dai, X.; OuYang, C.; Han, Y.M.; Xie, Z.; Zou, M.H. Deletion of PRKAA triggers mitochondrial fission by inhibiting the autophagy-dependent degradation of DNMI1. *Autophagy* 2017; 13, 404–422.

106. Wang, Z.; Wilson, W.A.; Fujino, M.A.; Roach, P.J. Antagonistic controls of autophagy and glycolgen accumulation by Snf1p, the yeast homolog of AMP-activated protein kinase, and the cyclin-dependent kinase Pho85p. *Mol. Cell. Biol.* 2001; 21, 5742–5752.

107. Meley, D.; Bauvy, C.; Houben-Weerts, J.H.; Dubbelhuis, P.F.; Helmond, M.T.; Codogno, P.; Meijer, A.J. AMP-activated protein kinase and the regulation of autophagic proteolysis. *J. Biol. Chem.* 2006; 281, 34870–34879.

108. Chan, E.Y. mTORC1 phosphorylates the ULK1-Atg13-FIP200 autophagy regulatory complex. *Sci. Signal.* 2009; 2, pe51.

109. Kim, J.; Kundu, M.; Viollet, B.; Guan, K.L. AMPK and mTORC1 regulate autophagy through direct phosphorylation of Ulk1. *Nat. Cell Biol.* 2011; 13, 132–141.
110. Egan, D.F.; Shackelford, D.B.; Mihaylova, M.M.; Gelino, S.; Kohnz, R.A.; Mair, W.; Vasquez, D.S.; Joshi, A.; Gwinn, D.M.; Taylor, R. et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. *Science* 2011, 331, 456–461.

111. Mottillo, E.P.; Desjardins, E.M.; Crane, J.D.; Smith, B.K.; Green, A.E.; Ducommun, S.; Henriksen, T.I.; Rebalka, I.A.; Razi, A.; Sakamoto, K. et al. Lack of adipocyte AMPK exacerbates insulin resistance and hepatic steatosis through brown and beige adipose tissue function. *Cell Metab.* 2016, 24, 118–129.

112. Bujak, A.L.; Crane, J.D.; Lally, J.S.; Ford, R.J.; Kang, S.J.; Rebalka, I.A.; Green, A.E.; Kemp, B.E.; Hawke, T.J.; Schertzer, J.D. et al. AMPK activation of muscle autophagy prevents fasting-induced hypoglycemia and myopathy during aging. *Cell Metab.* 2015, 21, 883–890.

113. Yang, C.S.; Kim, J.J.; Lee, H.M.; Jin, H.S.; Lee, S.H.; Park, J.H.; Kim, S.J.; Kim, J.M.; Han, Y.M.; Lee, M.S. et al. The AMPK-PPARGC1A pathway is required for antimicrobial host defense through activation of autophagy. *Autophagy* 2014, 10, 785–802.

114. Inokuchi-Shimizu, S.; Park, E.J.; Roh, Y.S.; Yang, L.; Zhang, B.; Song, J.; Liang, S.; Pimienta, M.; Taniguchi, K.; Wu, X. et al. TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis. *J. Clin. Invest.* 2014, 124, 3566–3578.

115. Jin, S.M.; Youle, R.J. PINK1- and Parkin-mediated mitophagy at a glance. *J. Cell Sci.* 2012, 125, 795–799.

116. McLeod, L.E.; Proud, C.G. ATP depletion increases phosphorylation of elongation factor eEF2 in adult cardiomyocytes independently of inhibition of mTOR signalling. *FEBS Lett.* 2002, 531, 448–452.

117. Wang, B.; Nie, J.; Wu, L.; Hu, Y.; Wen, Z.; Dong, L.; Zou, M.H.; Chen, C.; Wang, D.W. AMPKalpha2 protects against the development of heart failure by enhancing mitophagy via pink1 phosphorylation. *Circ. Res.* 2018, 122, 712–729.

118. Finkel, T.; Menazza, S.; Holmstrom, K.M.; Parks, R.J.; Liu, J.; Sun, J.; Liu, J.; Pan, X.; Murphy, E. The ins and outs of mitochondrial calcium. *Circ. Res.* 2015, 116, 1810–1819.

119. Kamer, K.J.; Mootha, V.K. The molecular era of the mitochondrial calcium uniporter. *Nat. Rev. Mol. Cell Biol.* 2015, 16, 545–553.

120. De Stefani, D.; Rizzuto, R.; Pozzan, T. Enjoy the trip: Calcium in mitochondria back and forth. *Annu. Rev. Biochem.* 2016, 85, 161–192.

121. De Stefani, D.; Raffaello, A.; Tearo, E.; Szabó, I.; Rizzuto, R. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. *Nature* 2011, 476, 336–340.

122. Baughman, J.M.; Perocchi, F.; Girgis, H.S.; Plovanich, M.; Belcher-Timme, C.A.; Sancak, Y.; Bao, X.R.; Strittmatter, L.; Goldberger, O.; Bogorad, R.L. et al. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. *Nature* 2011, 476, 341–345.

123. Chaudhuri, D.; Sancak, Y.; Mootha, V.K.; Clapham, D.E. MCU encodes the pore conducting mitochondrial calcium currents. *Elife* 2013, 2, e00704.

124. Mammucari, C.; Raffaello, A.; Vecellio Reane, D.; Gherardi, G.; De Mario, A.; Rizzuto, R. Mitochondrial calcium uptake in organ physiology: From molecular mechanism to animal models. *Pflugers Arch.* 2018, 470, 1165–1179.

125. Mammucari, C.; Gherardi, G.; Zamparo, I.; Raffaello, A.; Boncompagni, S.; Chemello, F.; Cagnin, S.; Braga, A.; Zanin, S.; Pallafacchina, G. et al. The mitochondrial calcium uniporter controls skeletal muscle trophism in vivo. *Cell Rep.* 2015, 10, 1269–1279.

126. Pan, X.; Liu, J.; Nguyen, T.; Liu, C.; Sun, J.; Teng, Y.; Fergusson, M.M.; Rovira, I.L.; Allen, M.; Springer, D.A. et al. The physiological role of mitochondrial calcium revealed by mice lacking the mitochondrial calcium uniporter. *Nat. Cell Biol.* 2013, 15, 1464–1472.

127. Zhao, H.; Li, T.; Wang, K.; Zhao, F.; Chen, J.; Xu, G.; Zhao, J.; Li, T.; Chen, L.; Li, L. et al. AMPK-mediated activation of MCU stimulates mitochondrial Ca(2+) entry to promote mitotic progression. *Nat. Cell Biol.* 2019, 21, 476–486.

128. Wang, Q.; Zhang, M.; Liang, B.; Shivrany, N.; Zhu, Y.; Zou, M.H. Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: The role of uncoupling protein 2. *PLoS ONE* 2011, 6, e25436.

129. Ou, H.C.; Chou, W.C.; Chu, P.M.; Hsieh, P.L.; Hung, C.H.; Tsai, K.L. Fucoxanthin protects against oxoLDL-induced endothelial damage via activating the AMPK-Akt-CREB-PGC1alpha pathway. *Mol. Nutr. Food Res.* 2019, 63, e1801353.
130. Xing, S.S.; Yang, X.Y.; Zheng, T.; Li, W.J.; Wu, D.; Chi, J.Y.; Bian, F.; Bai, X.L.; Wu, G.J.; Zhang, Y.Z. et al. Salidroside improves endothelial function and alleviates atherosclerosis by activating a mitochondria-related PI3K/Akt/eNOS pathway. *Vascul. Pharmacol.* 2015, 72, 141–152.

131. Karmewar, S.; Vasamsetti, S.B.; Gopoju, R.; Kanugula, A.K.; Ganji, S.K.; Prabhakar, S.; Rangaraj, N.; Tupperwar, N.; Kumar, J.M.; Kotamaraju, S. Mitochondria-targeted esculetin alleviates mitochondrial dysfunction by AMPK-mediated nitric oxide and SIRT3 regulation in endothelial cells: Potential implications in atherosclerosis. *Sci. Rep.* 2016, 6, 24108.

132. Xu, M.J.; Song, P.; Shirwany, N.; Liang, B.; Xing, J.; Violett, B.; Wang, X.; Zhu, Y.; Zou, M.H. Impaired expression of uncoupling protein 2 causes defective postischemic angiogenesis in mice deficient in AMPK-activated protein kinase alpha subunits. *Arterioscler. Thromb. Vasc. Biol.* 2011, 31, 1757–1765.

133. Zhang, H.; Liu, B.; Li, T.; Zhu, Y.; Luo, G.; Jiang, Y.; Tang, F.; Jian, Z.; Xiao, Y. AMPK activation serves a critical role in mitochondria quality control via modulating mitophagy in the heart under chronic hypoxia. *Int. J. Mol. Med.* 2018, 41, 69–76.

134. Zhou, H.; Zhang, Y.; Hu, S.; Shi, C.; Zhu, P.; Ma, Q.; Jin, Q.; Cao, F.; Tian, F.; Chen, Y. Melatonin protects cardiac microvasculature against ischemia/reperfusion injury via suppression of mitochondrial fission-VDAC1-HK2-mPTP-mitophagy axis. *J. Pineal. Res.* 2017, 63.

135. Kamga Pride, C.; Mo, L.; Quesnelle, K.; Dagda, R.K.; Murillo, D.; Geary, L.; Corey, C.; Portella, R.; Zharkov, S.; St Croix, C. et al. Nitrite activates protein kinase A in normoxia to mediate mitochondrial fusion and tolerance to ischaemia/reperfusion. *Cardiovasc. Res.* 2014, 101, 57–68.

136. Wei, M.; Gan, L.; Liu, Z.; Liu, L.; Chang, J.R.; Yin, D.C.; Cao, H.L.; Xu, X.L.; Smith, W.W. Mitochondria-derived peptide MOTS-c attenuates vascular calcification and secondary myocardial remodeling via adenosine monophosphate-activated protein kinase signaling pathway. *Cardiovasc. Med.* 2020, 10, 42–50.

137. Wu, L.P.; Gong, Z.F.; Wang, H.; Zhou, Z.S.; Zhang, M.M.; Liu, C.; Ren, H.M.; Yang, J.; Han, Y.; Zeng, C.Y. TSPO ligands prevent the proliferation of vascular smooth muscle cells and attenuate neointima formation through AMPK activation. *Acta Pharmacol. Sin.* 2020, 41, 34–46.

138. Zhang, M.; Wu, J.; Sun, R.; Tao, X.; Wang, X.; Kang, Q.; Wang, H.; Zhang, L.; Liu, P.; Zhang, J. et al. SIRT5 deficiency suppresses mitochondrial ATP production and promotes AMPK activation in response to energy stress. *PLoS ONE* 2019, 14, e0211796.

139. Wu, S.; Lu, Q.; Ding, Y.; Wu, Y.; Qiu, Y.; Wang, P.; Mao, X.; Huang, K.; Xie, Z.; Zou, M.H. Hyperglycemia-Driven Inhibition of AMP-activated protein kinase alpha2 induces diabetic cardiomyopathy by promoting mitochondria-associated endoplasmic reticulum membranes in vivo. *Circulation* 2019, 139, 1913–1936.

140. Cui, J.; Li, Z.; Zhuang, S.; Qi, S.; Li, L.; Zhou, J.; Zhang, W.; Zhao, Y. Melatonin alleviates inflammation-induced apoptosis in human umbilical vein endothelial cells via suppression of Ca(2+)-XO-ROS-Drp1-mitochondrial fission axis by activation of AMPK/SERCA2a pathway. *Cell Stress Chaperones* 2018, 23, 281–293.

141. Li, Y.; Zhou, Z.H.; Chen, M.H.; Yang, J.; Leng, J.; Cao, G.S.; Xin, G.Z.; Liu, L.F.; Kou, J.P.; Liu, B.L. et al. Inhibition of mitochondrial fission and NOX2 expression prevent nlrp3 inflammasome activation in the endothelium: The role of corosolic acid action in the amelioration of endothelial dysfunction. *Antioxid. Redox Signal.* 2016, 24, 893–908.

142. Cao, K.; Xu, J.; Pu, W.; Dong, Z.; Sun, L.; Zhang, W.; Gao, F.; Zhang, Y.; Feng, Z.; Liu, J. Punicalagin, an active component in pomegranate, ameliorates cardiac mitochondrial impairment in obese rats via AMPK activation. *Sci. Rep.* 2015, 5, 14014.

143. Singh, R.B.; Mengi, S.A.; Xu, Y.J.; Arneja, A.S.; Dhalla, N.S. Pathogenesis of atherosclerosis: A multifactorial process. *Exp. Clin. Cardiol.* 2002, 7, 40–53.

144. Maruyama, I. Biology of endothelium. *Lupus 1998, 7 Suppl 2, S41–43.*

145. Jansen, T.; Kvandová, M.; Daiber, A.; Stamm, P.; Frenis, K.; Schulz, E.; Münzel, T.; Kröller-Schön, S. The AMP-activated protein kinase plays a role in antioxidant defense and regulation of vascular inflammation. *Antioxidants (Basel)* 2020, 9.

146. Horimoto, M.; Resnick, M.B.; Konkin, T.A.; Routhier, J.; Wands, J.R.; Baffy, G. Expression of uncoupling protein-2 in human colon cancer. *Clin. Cancer Res.* 2004, 10, 6203–6207.

147. Horimoto, M.; Fulop, P.; Derdak, Z.; Wands, J.R.; Baffy, G. Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in mice. *Hepatology* 2004, 39, 386–392.

148. Blanc, J.; Alves-Guerra, M.C.; Esposito, B.; Rouset, S.; Gourdy, P.; Ricquier, D.; Tedgui, A.; Miroux, B.; Mallat, Z. Protective role of uncoupling protein 2 in atherosclerosis. *Circulation* 2003, 107, 388–390.
149. Arsenijevic, D.; Onuma, H.; Pecqueur, C.; Raimbault, S.; Manning, B.S.; Miroux, B.; Couplan, E.; Alves-Guerra, M.C.; Gouburn, M.; Surwit, R. et al. Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production. *Nat. Genet.* 2000, 26, 435–439.

150. Negre-Salvayre, A.; Hirtz, C.; Carrera, G.; Cazenave, R.; Troy, M.; Salvayre, R.; Penicaud, L.; Castella, L. A role for uncoupling protein-2 as a regulator of mitochondrial hydrogen peroxide generation. *FASEB J.* 1997, 11, 809–815.

151. McCarty, M.F.; Barroso-Aranda, J.; Contreras, F. AMP-activated kinase may suppress NADPH oxidase activation in vascular tissues. *Med. Hypotheses* 2009, 72, 468–470.

152. Ou, H.C.; Hsieh, Y.L.; Yang, N.C.; Tsai, K.L.; Chen, K.L.; Tsai, C.S.; Chen, I.J.; Wu, B.T.; Lee, S.D. Ginkgo biloba extract attenuates oxLDL-induced endothelial dysfunction via an AMPK-dependent mechanism. *J. Appl. Physiol.* (1985) 2013, 114, 274–285.

153. Chen, J.Y.; Ye, Z.X.; Wang, X.F.; Chang, J.; Yang, M.W.; Zhong, H.H.; Hong, F.F.; Yang, S.L. Nitric oxide bioavailability dysfunction involves in atherosclerosis. *Biomed. Pharmacother.* 2018, 97, 423–428.

154. Davignon, J.; Ganz, P. Role of endothelial dysfunction in atherosclerosis. *Circulation* 2004, 109, IIi27–IIi32.

155. Li, A.C.; Glass, C.K. The macrophage foam cell as a target for therapeutic intervention. *Nat. Med.* 2002, 8, 1235–1242.

156. Davis, B.J.; Xie, Z.; Violett, B.; Zou, M.H. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. *Diabetes* 2006, 55, 496–505.

157. Chen, H.; Montagnani, M.; Funahashi, T.; Shimomura, I.; Quon, M.J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. *J. Biol. Chem.* 2003, 278, 45021–45026.

158. Thors, B.; Halldorsson, H.; Jonsdottir, G.; Thorgerisson, G. Mechanism of thrombin mediated eNOS phosphorylation in endothelial cells is dependent on ATP levels after stimulation. *Biochim. Biophys. Acta* 2008, 1783, 1893–1902.

159. Thors, B.; Halldorsson, H.; Thorgerisson, G. Thrombin and histamine stimulate endothelial nitric-oxide synthase phosphorylation at Ser1177 via an AMPK mediated pathway independent of PI3K-Akt. *FEBS Lett.* 2004, 573, 175–180.

160. Wang, Y.; Huang, Y.; Lam, K.S.; Li, Y.; Wong, W.T.; Ye, H.; Lau, C.W.; Vanhoutte, P.M.; Xu, A. Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. *Cardiovasc. Res.* 2009, 82, 484–492.

161. Xu, L.; Wang, S.; Li, B.; Sun, A.; Zou, Y.; Ge, J. A protective role of ciglitazone in ox-LDL-induced rat microvascular endothelial cells via modulating PPARgamma-dependent AMPK/eNOS pathway. *J. Cell. Mol. Med.* 2015, 19, 92–102.

162. Levine, Y.C.; Li, G.K.; Michel, T. Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells. Evidence for an AMPK → Rac1 → Akt → endothelial nitric-oxide synthase pathway. *J. Biol. Chem.* 2007, 282, 20351–20364.

163. Chen, Z.; Peng, I.C.; Sun, W.; Su, M.I.; Hsu, P.H.; Fu, Y.; Zhu, Y.; DeFea, K.; Pan, S.; Tsai, M.D. et al. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. *Circ. Res.* 2009, 104, 496–505.

164. Ouchi, N.; Kobayashi, H.; Kihara, S.; Kumada, M.; Sato, K.; Inoue, T.; Funahashi, T.; Walsh, K. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. *J. Biol. Chem.* 2004, 279, 1304–1309.

165. Nagata, D.; Mogi, M.; Walsh, K. AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. *J. Biol. Chem.* 2003, 278, 31000–31006.

166. Kaneko, T.; Baba, N.; Matsuo, M. Structure-activity relationship of antioxidants for inhibitors of linoleic acid hydroperoxide-induced toxicity in cultured human umbilical vein endothelial cells. *Cytotechnology* 2001, 35, 43–55.

167. Heil, M.; Eitenmuller, I.; Schmitz-Rixen, T.; Schaper, W. Arteriogenesis versus angiogenesis: Similarities and differences. *J. Cell. Mol. Med.* 2006, 10, 45–55.

168. Schaper, J.; Meiser, E.; Stammler, G. Ultrastructural morphometric analysis of myocardium from dogs, rats, hamsters, mice, and from human hearts. *Circ. Res.* 1985, 56, 377–391.
169. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018, 392, 1789–1858.

170. Young, L.H. AMP-activated protein kinase conducts the ischemic stress response orchestra. *Circulation* 2008, 117, 832–840.

171. Miller, E.J.; Li, J.; Leng, L.; McDonald, C.; Atsumi, T.; Bucala, R.; Young, L.H. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. *Nature* 2008, 451, 578–582.

172. Ma, H.; Wang, J.; Thomas, D.P.; Tong, C.; Leng, L.; Wang, W.; Merk, M.; Zierow, S.; Bernhagen, J.; Ren, J. et al. Impaired macrophage migration inhibitory factor-AMP-activated protein kinase activation and ischemic recovery in the senescent heart. *Circulation* 2010, 122, 282–292.

173. Russell, R.R.; 3rd; Li, J.; Coven, D.L.; Pypaert, M.; Zechnier, C.; Palmeri, M.; Giordano, F.J.; Mu, J.; Birnbaum, M.J.; Young, L.H. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. *J. Clin. Invest.* 2004, 114, 495–503.

174. Kornosky, J.L.; Salihu, H.M. Getting to the heart of the matter: Epidemiology of cyanotic heart defects. *Pediatr. Cardiol.* 2008, 29, 484–497.

175. Zhu, L.; Wang, Q.; Zhang, L.; Fang, Z.; Zhao, F.; Lv, Z.; Gu, Z.; Zhang, J.; Wang, J.; Zen, K. et al. Hypoxia induces PGC-1alpha expression and mitochondrial biogenesis in the myocardium of TOF patients. *Cell Res.* 2010, 20, 676–687.

176. Fischer, F.; Hamann, A.; Osiewacz, H.D. Mitochondrial quality control: An integrated network of pathways. *Trends Biochem. Sci.* 2012, 37, 284–292.

177. Dauber, I.M.; VanBenthuyzen, K.M.; McMurry, I.F.; Wheeler, G.S.; Lesniewsky, E.J.; Horwitz, L.D.; Weil, J.V. Functional coronary microvascular injury evident as increased permeability due to brief ischemia and reperfusion. *Circ. Res.* 1990, 66, 986–998.

178. Weir, R.A.; Murphy, C.A.; Petrie, C.J.; Martin, T.N.; Balmain, S.; Clements, S.; Steedman, T.; Wagner, G.S.; Dargie, H.J.; McMurray, J.J. Microvascular obstruction remains a portent of adverse remodeling in optimally treated patients with left ventricular systolic dysfunction after acute myocardial infarction. *Circ. Cardiovasc. Imaging* 2010, 3, 360–367.

179. Kloner, R.A.; Ganote, C.E.; Jennings, R.B. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. *J. Clin. Invest.* 1974, 54, 1496–1508.

180. Abbate, A.; Kontos, M.C.; Biondi-Zoccai, G.G. No-reflow: The next challenge in treatment of ST-elevation acute myocardial infarction. *Eur. Heart J.* 2008, 29, 1795–1797.

181. Ndrepepa, G.; Tiroch, K.; Fusaro, M.; Keta, D.; Seyfarth, M.; Byrne, R.A.; Pache, J.; Alger, P.; Mehilli, J.; Schomig, A. et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. *J. Am. Coll. Cardiol.* 2010, 55, 2383–2389.

182. Hu, H.; Li, X.; Ren, D.; Tan, Y.; Chen, J.; Yang, L.; Chen, R.; Li, J.; Zhu, P. The cardioprotective effects of carvedilol on ischemia and reperfusion injury by AMPK signaling pathway. *Biomed. Pharmacother.* 2019, 117, 109106.

183. Calvert, J.W.; Gundewar, S.; Jha, S.; Greer, J.J.; Bestermann, W.H.; Tian, R.; Lefer, D.J. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. *Diabetes* 2008, 57, 696–705.

184. Ji, W.; Wei, S.; Hao, P.; Xing, J.; Yuan, Q.; Wang, J.; Xu, F.; Chen, Y. Aldehyde dehydrogenase 2 has cardioprotective effects on myocardial ischaemia/reperfusion injury via suppressing mitophagy. *Front. Pharmacol.* 2016, 7, 101.

185. Lin, C.; Chao, H.; Li, Z.; Xu, X.; Liu, Y.; Hou, L.; Liu, N.; Ji, J. Melatonin attenuates traumatic brain injury-induced inflammation: A possible role for mitophagy. *J. Pineal. Res.* 2016, 61, 177–186.

186. Duranski, M.R.; Greer, J.J.; Dejam, A.; Jaganmohan, S.; Hogg, N.; Langston, W.; Patel, R.P.; Yet, S.F.; Wang, X.; Kevil, C.G. et al. Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. *J. Clin. Invest.* 2005, 115, 1223–1240.

187. Tripathara, P.; Patel, N.S.; Webb, A.; Rathod, K.; Lecomte, F.M.; Mazzon, E.; Cuzzocrea, S.; Yaqoob, M.M.; Ahluwalia, A.; Thiemermann, C. Nitrite-derived nitric oxide protects the rat kidney against ischemia/reperfusion injury in vivo: Role for xanthine oxidoreductase. *J. Am. Soc. Nephrol.* 2007, 18, 570–580.
188. Jung, K.H.; Chu, K.; Ko, S.Y.; Lee, S.T.; Sinn, D.I.; Park, D.K.; Kim, J.M.; Song, E.C.; Kim, M.; Roh, J.K. Early intravenous infusion of sodium nitrite protects brain against in vivo ischemia-reperfusion injury. *Stroke* **2006**, *37*, 2744–2750.

189. Dezfuzian, C.; Raat, N.; Shiva, S.; Gladwin, M.T. Role of the anion nitrite in ischemia-reperfusion cytoprotection and therapeutics. *Cardiovasc. Res.* **2007**, *75*, 327–338.

190. Webb, A.; Bond, R.; McLean, P.; Uppal, R.; Benjamin, N.; Ahluwalia, A. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 13683–13688.

191. Kumar, D.; Branch, B.G.; Pattillo, C.B.; Hood, J.; Thoma, S.; Simpson, S.; Illum, S.; Arora, N.; Chidlow, J.H., Jr.; Langston, W. et al. Chronic sodium nitrite therapy augments ischemia-induced angiogenesis and arteriogenesis. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 7540–7545.

192. Lundberg, J.O.; Weitzberg, E.; Gladwin, M.T. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. *Nat. Rev. Drug Discov.* **2008**, *7*, 156–167.

193. Lee, C.; Zeng, J.; Drew, B.G.; Sallam, T.; Martin-Montalvo, A.; Wan, J.; Kim, S.J.; Mehta, H.; Hevener, A.L.; de Cabo, R. et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. *Cell Metab.* **2015**, *21*, 443–454.

194. Kim, N.; Jung, Y.; Nam, M.; Sun Kang, M.; Lee, M.K.; Cho, Y.; Choi, E.K.; Hwang, G.S.; Soo Kim, H. Angiotensin II affects inflammation mechanisms via AMPK-related signalling pathways in HL-1 atrial myocytes. *Sci. Rep.* **2017**, *7*, 10328.

195. Chen, Y.; Zhang, H.; Liu, H.; Li, K.; Su, X. Homocysteine up-regulates ETB receptors via suppression of autophagy in vascular smooth muscle cells. *Microvasc. Res.* **2018**, *119*, 13–21.

196. Schwartz, S.M. Perspectives series: Cell adhesion in vascular biology. Smooth muscle migration in atherosclerosis and restenosis. *J. Clin. Invest.* **1997**, *99*, 2814–2816.

197. Chan, A.Y.; Dolinsky, V.W.; Soltys, C.L.; Viollet, B.; Baksh, S.; Light, P.E.; Dyck, J.R. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. *J. Biol. Chem.* **2008**, *283*, 24194–24201.

198. Chan, A.Y.; Soltys, C.L.; Young, M.E.; Proud, C.G.; Dyck, J.R. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. *J. Biol. Chem.* **2004**, *279*, 32771–32779.

199. Browne, G.J.; Finn, S.G.; Proud, C.G. Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398. *J. Biol. Chem.* **2004**, *279*, 12220–12231.

200. Ikeda, Y.; Sato, K.; Pimentel, D.R.; Sam, F.; Shaw, R.J.; Dyck, J.R.; Walsh, K. Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction. *J. Biol. Chem.* **2009**, *284*, 35839–35849.

201. Zaha, V.G.; Young, L.H. AMP-activated protein kinase regulation and biological actions in the heart. *Circ. Res.* **2012**, *111*, 800–814.

202. Turdi, S.; Fan, X.; Li, J.; Zhao, J.; Huff, A.F.; Du, M.; Ren, J. AMP-activated protein kinase deficiency exacerbates aging-induced myocardial contractile dysfunction. *Aging Cell* **2010**, *9*, 592–606.

203. Feng, D.; Bitu, T.; Romero, F.A.; Kekec, A.; Dropinski, J.; Kassick, A.; Xu, S.; Kurtz, M.M.; Gollapudi, A.; Shao, Q. et al. Discovery of MK-8722: A systemic, direct pan-activator of amp-activated protein kinase. *ACS Med. Chem. Lett.* **2018**, *9*, 39–44.

204. Schlicker, C.; Gertz, M.; Papathедorou, P.; Kachholz, B.; Becker, C.F.; Steegborn, C. Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. *J. Mol. Biol.* **2008**, *382*, 790–801.

205. Nakagawa, T.; Lomb, D.J.; Haigis, M.C.; Gavriante, L. SIRT5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. *Cell* **2009**, *137*, 560–570.

206. Tong, M.; Saito, T.; Zhai, P.; Oka, S.I.; Mizushima, W.; Nakamura, M.; Ikeda, S.; Shirakabe, A.; Sadoshima, J. Mitophagy is essential for maintaining cardiac function during high fat diet-induced diabetic cardiomyopathy. *Circ. Res.* **2019**, *124*, 1360–1371.

207. Cahill, T.J.; Leo, V.; Kelly, M.; Stockenhuber, A.; Kennedy, N.W.; Bao, L.; Cereghetti, G.M.; Harper, A.R.; Czibik, G.; Liao, C. et al. Resistance of dynamin-related protein 1 oligomers to disassembly impairs mitophagy, resulting in myocardial inflammation and heart failure. *J. Biol. Chem.* **2016**, *291*, 25762.

208. Ikeda, Y.; Shirakabe, A.; Maejima, Y.; Zhai, P.; Sciarretta, S.; Toli, J.; Nomura, M.; Mihara, K.; Egashira, K.; Ohishi, M. et al. Endogenous Drp1 mediates mitochondrial autophagy and protects the heart against energy stress. *Circ. Res.* **2015**, *116*, 264–278.
Int. J. Mol. Sci. 2020, 21, 4987

209. Oka, T.; Hikosho, S.; Yamaguchi, O.; Taneike, M.; Takeda, T.; Tamai, T.; Oyabu, J.; Murakawa, T.; Nakayama, H.; Nishida, K. et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 2012, 485, 251–255.

210. Kitada, T.; Asakawa, S.; Hattori, N.; Matsumine, H.; Yamamura, Y.; Minoshima, S.; Yokochi, M.; Mizuno, Y.; Shimizu, N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392, 605–608.

211. Valente, E.M.; Abou-Sleiman, P.M.; Caputo, V.; Muquit, M.M.; Harvey, K.; Gispert, S.; Ali, Z.; Del Turco, D.; Bentivoglio, A.R.; Healy, D.G. et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 2004, 304, 1158–1160.

212. Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016, 387, 1513–1530.

213. Kolb, H.; Martin, S. Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes. BMC Med. 2017, 15, 131.

214. Sena, C.M.; Pereira, A.M.; Seica, R. Endothelial dysfunction—A major mediator of diabetic vascular disease. Biochim. Biophys. Acta 2013, 1832, 2216–2231.

215. Forbes, J.M.; Cooper, M.E. Mechanisms of diabetic complications. Physiol. Rev. 2013, 93, 137–188.

216. Zhang, H.; Dellsperger, K.C.; Zhang, C. The link between metabolic abnormalities and endothelial dysfunction in type 2 diabetes: An update. Basic Res. Cardiol. 2012, 107, 237.

217. Kim, J.A.; Montagnani, M.; Koh, K.K.; Quon, M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: Molecular and pathophysiological mechanisms. Circulation 2006, 113, 1888–1904.

218. Wang, Q.; Zhang, M.; Torres, G.; Wu, S.; Ouyang, C.; Xie, Z.; Zou, M.H. Metformin suppresses diabetes-accelerated atherosclerosis via the inhibition of drp1-mediated mitochondrial fission. Diabetes 2017, 66, 193–205.

219. Sorrentino, V.; Menzies, K.J.; Auwerx, J. Repairing mitochondrial dysfunction in disease. Annu. Rev. Pharmacol. Toxicol. 2018, 58, 353–389.

220. Forbes, J.M.; Fotheringham, A.K. Vascular complications in diabetes: Old messages, new thoughts. Diabetologia 2017, 60, 2129–2138.

221. Gioscia-Ryan, R.A.; LaRocca, T.J.; Sindler, A.L.; Zigler, M.C.; Murphy, M.P.; Seals, D.R. Mitochondria-targeted antioxidant (MitoQ) ameliorates age-related arterial endothelial dysfunction in mice. J. Physiol. 2014, 592, 2549–2561.

222. Huang, M.; Wei, R.; Wang, Y.; Su, T.; Li, P.; Chen, X. The uremic toxin hippurate promotes endothelial dysfunction via the activation of Drp1-mediated mitochondrial fission. Redox Biol. 2018, 16, 303–313.

223. Yu, T.; Robotham, J.L.; Yoon, Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc. Natl. Acad. Sci. USA 2006, 103, 2653–2658.

224. Shigenaga, M.K.; Hagen, T.M.; Ames, B.N. Oxidative damage and mitochondrial decay in aging. Proc. Natl. Acad. Sci. USA 1994, 91, 10771–10778.

225. Green, K.; Brand, M.D.; Murphy, M.P. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 2004, 53 Suppl 1, S110–118.

226. Brand, M.D. Mitochondrial generation of superoxide and hydrogen peroxide as the source of mitochondrial redox signaling. Free Radic. Biol. Med. 2016, 100, 14–31.

227. Lu, Q.; Li, X.; Liu, J.; Sun, X.; Rousselle, T.; Ren, D.; Tong, N.; Li, J. AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases. Biosci. Rep. 2019, 39.

228. Ren, L.; Han, F.; Xuan, L.; Lv, Y.; Gong, L.; Yan, Y.; Wan, Z.; Guo, L.; Liu, H.; Xu, B. et al. Clusterin ameliorates endothelial dysfunction in diabetes by suppressing mitochondrial fragmentation. Free Radic. Biol. Med. 2019, 145, 357–373.

229. Zhou, H.; Wang, S.; Zhu, P.; Hu, S.; Chen, Y.; Ren, J. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol. 2018, 15, 335–346.

230. Liu, H.; Xiang, H.; Zhao, S.; Sang, H.; Lv, F.; Chen, R.; Shu, Z.; Chen, A.F.; Chen, S.; Lu, H. Vildagliptin improves high glucose-induced endothelial mitochondrial dysfunction via inhibiting mitochondrial fission. J. Cell. Mol. Med. 2019, 23, 798–810.

231. Jia, G.; Hill, M.A.; Sowers, J.R. Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity. Circ. Res. 2018, 122, 624–638.
232. Xie, Z.; Lau, K.; Eby, B.; Lozano, P.; He, C.; Pennington, B.; Li, H.; Rathi, S.; Dong, Y.; Tian, R. et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 2011, 60, 1770–1778.

233. Giorgi, C.; De Stefani, D.; Bononi, A.; Rizzuto, R.; Pinton, P. Structural and functional link between the mitochondrial network and the endoplasmic reticulum. Int. J. Biochem. Cell Biol. 2009, 41, 1817–1827.

234. Rowland, A.A.; Voeltz, G.K. Endoplasmic reticulum-mitochondria contacts: Function of the junction. Nat. Rev. Mol. Cell Biol. 2012, 13, 607–625.

235. Del Prete, D.; Suski, J.M.; Oules, B.; Debayle, D.; Gay, A.S.; Lacas-Gervais, S.; Bussiere, R.; Bauer, C.; Pinton, P.; Paterlini-Brechot, P. et al. Localization and processing of the amyloid-beta protein precursor in mitochondria-associated membranes. J. Alzheimers Dis. 2017, 55, 1549–1570.

236. Ando, H.; Kawai, K.; Bonneaud, B.; Mikoshiba, K. Remodeling of Ca(2+) signaling in cancer: Regulation of inositol 1,4,5-trisphosphate receptors through oncogenes and tumor suppressors. Adv. Biol. Regul. 2018, 68, 64–76.

237. Marchi, S.; Patergnani, S.; Pinton, P. The endoplasmic reticulum-mitochondria connection: One touch, multiple functions. Biochim. Biophys. Acta 2014, 1837, 461–469.

238. Betz, C.; Stracka, D.; Prescianotto-Baschong, C.; Frieden, M.; Demaurex, N.; Hall, M.N. Feature Article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology. Proc. Natl. Acad. Sci. USA 2013, 110, 12526–12534.

239. Tubbs, E.; Theurey, P.; Vial, G.; Bendridi, N.; Bravard, A.; Chauvin, M.A.; Ji-Cao, J.; Zoulim, F.; Bartosch, B.; Ovize, M. et al. Mitochondria-associated endoplasmic reticulum membrane (MAM) integrity is required for insulin signaling and is implicated in hepatic insulin resistance. Diabetes 2014, 63, 3279–3294.

240. Arruda, A.P.; Pers, B.M.; Farlagkul, G.; Guney, E.; Inouye, K.; Hotamisligil, G.S. Chronic enrichment of hepatic endoplasmic reticulum-mitochondria contact leads to mitochondrial dysfunction in obesity. Nat. Med. 2014, 20, 1427–1435.

241. Wu, S.; Lu, Q.; Wang, Q.; Ding, Y.; Ma, Z.; Mao, X.; Huang, K.; Xie, Z.; Zou, M.H. Binding of FUN14 domain containing 1 with inositol 1,4,5-trisphosphate receptor in mitochondria-associated endoplasmic reticulum membranes maintains mitochondrial dynamics and function in hearts in vivo. Circulation 2017, 136, 2248–2266.

242. Marui, N.; Offermann, M.K.; Swerlick, R.; Kunsch, C.; Rosen, C.A.; Ahmad, M.; Alexander, R.W.; Medford, R.M. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J. Clin. Invest. 1993, 92, 1866–1874.

243. Murao, K.; Ohyama, T.; Imachi, H.; Ishida, T.; Cao, W.M.; Namihira, H.; Sato, M.; Wong, N.C.; Takahara, J. TNF-alpha stimulation of MCP-1 expression is mediated by the Akt/PKB signal transduction pathway in vascular endothelial cells. Biochem. Biophys. Res. Commun. 2000, 276, 791–796.

244. Kirii, H.; Niwa, T.; Yamada, Y.; Wada, H.; Saito, K.; Iwakura, Y.; Asano, M.; Moriwaki, H.; Seishima, M. Lack of interleukin-1beta decreases the severity of atherosclerosis in Apo-E deficient mice. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 656–660.

245. Zhang, Y.; Lee, T.S.; Kolb, E.M.; Sun, K.; Lu, X.; Sladek, F.M.; Kassab, G.S.; Garland, T., Jr.; Shy, I.Y. AMP-activated protein kinase is involved in endothelial NO synthase activation through shear stress. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 1281–1287.

246. Caballero, A.E.; Delgado, A.; Aguilar-Salinas, C.A.; Herrera, A.N.; Castillo, J.L.; Cabrera, T.; Gomez-Perez, F.J.; Rull, J.A. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: A placebo-controlled, randomized clinical trial. J. Clin. Endocrinol. Metab. 2004, 89, 3943–3948.

247. Bergheim, I.; Luyendyk, J.P.; Steele, C.; Russell, G.K.; Guo, L.; Roth, R.A.; Arteel, G.E. Metformin prevents endotoxin-induced liver injury after partial hepatectomy. J. Pharmacol. Exp. Ther. 2006, 316, 1053–1061.

248. Ewart, M.A.; Kohlaas, C.F.; Salt, I.P. Inhibition of tumor necrosis factor alpha-stimulated monocyte adhesion to human aortic endothelial cells by AMP-activated protein kinase. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 2255–2257.

249. Zhang, Y.; Qiu, J.; Wang, X.; Zhang, Y.; Xia, M. AMP-activated protein kinase suppresses endothelial cell inflammation through phosphorylation of transcriptional coactivator p300. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 2897–2908.
250. Hawley, S.A.; Gadalla, A.E.; Olsen, G.S.; Hardie, D.G. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. *Diabetes* **2002**, *51*, 2420–2425.

251. Li, X.; Han, Y.; Pang, W.; Li, C.; Xie, X.; Shyy, J.Y.; Zhu, Y. AMP-activated protein kinase promotes the differentiation of endothelial progenitor cells. *Arterioscler. Thromb. Vasc. Biol.* **2008**, *28*, 1789–1795.

252. Nerstedt, A.; Johansson, A.; Andersson, C.X.; Cansby, E.; Smith, U.; Mahlapuu, M. AMP-activated protein kinase inhibits IL-6-stimulated inflammatory response in human liver cells by suppressing phosphorylation of signal transducer and activator of transcription 3 (STAT3). *Diabetologia* **2010**, *53*, 2406–2416.

253. Salminen, A.; Hyttinen, J.M.; Kaarniranta, K. AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: Impact on healthspan and lifespan. *J. Mol. Med. (Berl)* **2011**, *89*, 667–676.

254. Gongol, B.; Marin, T.; Peng, I.C.; Woo, B.; Martin, M.; King, S.; Sun, W.; Johnson, D.A.; Chien, S.; Shyy, J.Y. AMPKalpha2 exerts its anti-inflammatory effects through PARP-1 and Bel-6. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 3161–3166.

255. Hattori, Y.; Suzuki, K.; Hattori, S.; Kasai, K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. *Hypertension* **2006**, *47*, 1183–1188.

256. Mancini, S.J.; Boyd, D.; Katwan, O.J.; Strombatska, A.; Almabrouk, T.A.; Kennedy, S.; Palmer, T.M.; Salt, I.P. Canagliflozin inhibits interleukin-1beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. *Sci. Rep.* **2018**, *8*, 5276.

257. Barness, L.A.; Opitz, J.M.; Gilbert-Barness, E. Obesity: Genetic, molecular, and environmental aspects. *Am. J. Med. Genet. A* **2007**, *143a*, 3016–3034.

258. Boden, G. Effects of free fatty acids (FFA) on glucose metabolism: Significance for insulin resistance and type 2 diabetes. *Exp. Clin. Endocrinol. Diabetes* **2003**, *111*, 121–124.

259. Dresner, A.; Laurent, D.; Marcucci, M.; Griffin, M.E.; Dufour, S.; Cline, G.W.; Slezak, L.A.; Andersen, D.K.; Hundal, R.S.; Rothman, D.L. et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. *J. Clin. Invest.* **1999**, *103*, 253–259.

260. Inoguchi, T.; Li, P.; Umeda, F.; Yu, H.Y.; Kakimoto, M.; Imamura, M.; Aoki, T.; Etoh, T.; Hashimoto, T.; Naruse, M. et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C–dependent activation of NAD(P)H oxidase in cultured vascular cells. *Diabetes* **2000**, *49*, 1939–1945.

261. Engin, A. Endothelial dysfunction in obesity. *Adv. Exp. Med. Biol.* **2017**, *960*, 345–379.

262. Harmanecy, R.; Wilson, C.R.; Taegtmeyer, H. Adaptation and maladaptation of the heart in obesity. *Hypertension* **2008**, *52*, 181–187.

263. Louwe, M.C.; van der Hoorn, J.W.; van den Berg, S.A.; Jukema, J.W.; Romijn, J.A.; van Dijk, K.W.; Rensen, P.C.; Smit, J.W.; Steendijk, P. Gender-dependent effects of high-fat lard diet on cardiac function in C57BL/6J mice. *Appl. Physiol. Nutr. Metab.* **2012**, *37*, 214–224.

264. Schram, K.; Sweeney, G. Implications of myocardial matrix remodeling by adipokines in obesity-related heart failure. *Trends Cardiovasc. Med.* **2008**, *18*, 199–205.

265. Lamouneir-Zeppter, V.; Look, C.; Alvarez, J.; Christ, T.; Ravens, U.; Schunck, W.H.; Ehrhart-Bornstein, M.; Bornstein, S.R.; Morano, I. Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: A new link between obesity and heart disease. *Circ. Res.* **2009**, *105*, 326–334.

266. Lindholm, C.R.; Ertel, R.L.; Bauwens, J.D.; Schmuck, E.G.; Mulligan, J.D.; Sause, K.W. A high-fat diet decreases AMPK activity in multiple tissues in the absence of hyperglycemia or systemic inflammation in rats. *J. Physiol. Biochem.* **2013**, *69*, 165–175.

267. Shao, D.; Oka, S.; Liu, T.; Zhai, P.; Ago, T.; Siciarretta, S.; Li, H.; Sadoshima, J. A redox-dependent mechanism for regulation of AMPK activation by thioredoxin1 during energy starvation. *Cell Metab.* **2014**, *19*, 232–245.

268. Turdi, S.; Kandadi, M.R.; Zhao, J.; Huff, A.F.; Du, M.; Ren, J. Deficiency in AMP-activated protein kinase exaggerates high fat diet-induced cardiac hypertrophy and contractile dysfunction. *J. Mol. Cell. Cardiol.* **2011**, *50*, 712–722.
269. Zuo, A.; Zhao, X.; Li, T.; Li, J.; Lei, S.; Chen, J.; Xu, D.; Song, C.; Liu, T.; Li, C. et al. CTRP9 knockout exaggerates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy through inhibiting the LKB1/AMPK pathway. *J. Cell. Mol. Med.* **2020**, *24*, 2635–2647.

270. Bussey, C.T.; Thaung, H.P.A.; Hughes, G.; Bahn, A.; Lamberts, R.R. Cardiac beta-adrenergic responsiveness of obese Zucker rats: The role of AMPK. *Exp. Physiol.* **2018**, *103*, 1067–1075.

271. Anderson, E.J.; Kypson, A.P.; Rodriguez, E.; Anderson, C.A.; Lehr, E.J.; Neufer, P.D. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. *J. Am. Coll. Cardiol.* **2009**, *54*, 1891–1898.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).